[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 380
1. Khoo JJ, Alwi RI, Abd-Rahman I: Myoid hamartoma of breast with chondroid metaplasia: a case report. Malays J Pathol; 2009 Jun;31(1):77-80
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoid hamartoma of breast with chondroid metaplasia: a case report.
  • Breast hamartoma is an uncommon poorly recognised benign breast neoplasm.
  • Hamartoma displaying marked smooth muscle components known as myoid hamartoma of the breast is a much rarer entity.
  • We present a case of myoid hamartoma of breast with chondroid differentiation in a 46-year-old woman.
  • The painless breast lump was circumscribed and mammography showed a well-encapsulated large, dense mass with no calcification.
  • The various immuno-histochemical staining as well as the cyto-histological changes encountered in myoid hamartomas are discussed with clinical, radiological and pathological correlation to differentiate it from other benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / pathology. Hamartoma / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Biomarkers / metabolism. Breast Neoplasms / diagnosis. Cartilage / pathology. Cell Differentiation. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Humans. Immunohistochemistry. Metaplasia / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694319.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


2. Huang YL, Chen DR, Jiang YR, Kuo SJ, Wu HK, Moon WK: Computer-aided diagnosis using morphological features for classifying breast lesions on ultrasound. Ultrasound Obstet Gynecol; 2008 Sep;32(4):565-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided diagnosis using morphological features for classifying breast lesions on ultrasound.
  • OBJECTIVES: To develop and evaluate a computer-aided diagnosis (CAD) system with automatic contouring and morphological analysis to aid in the classification of breast tumors using ultrasound.
  • METHODS: We evaluated 118 breast lesions (34 malignant and 84 benign tumors).
  • Each tumor contour was automatically extracted from the digitized ultrasound image.
  • A support vector machine (SVM) classifier utilized the selected principal vectors to identify the breast tumor as benign or malignant.
  • The classification ability for breast tumors using morphological information was good.
  • CONCLUSIONS: This system differentiates benign from malignant breast tumors well and therefore provides a clinically useful second opinion.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Diagnosis, Computer-Assisted / methods. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Algorithms. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Principal Component Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383556.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


3. Huang YL, Kuo SJ, Chang CS, Liu YK, Moon WK, Chen DR: Image retrieval with principal component analysis for breast cancer diagnosis on various ultrasonic systems. Ultrasound Obstet Gynecol; 2005 Oct;26(5):558-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image retrieval with principal component analysis for breast cancer diagnosis on various ultrasonic systems.
  • OBJECTIVES: We present a computer-aided diagnostic (CAD) system with textural features and image retrieval strategies for classifying benign and malignant breast tumors on various ultrasonic systems.
  • This study evaluated a series of pathologically proven breast tumors using various ultrasonic systems.
  • METHODS: Altogether, 600 ultrasound images of solid breast nodules comprising 230 malignant and 370 benign tumors were investigated.
  • The suspicious tumor area in the ultrasound image was manually chosen as the region-of-interest (ROI) subimage.
  • Textural features extracted from the ROI subimage are supported in classifying the breast tumor as benign or malignant.
  • In practice, high-dimensional vectors are unsatisfactory at differentiating breast tumors.
  • The image retrieval techniques were employed to differentiate breast tumors, according to the similarities of the principal vectors.
  • The query ROI subimages were identified as malignant or benign tumors according to characteristics of retrieved images from the ultrasound image database.
  • CONCLUSION: The CAD system identified solid breast nodules with comparatively high accuracy in the different ultrasound systems investigated.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Image Interpretation, Computer-Assisted / methods
  • [MeSH-minor] Area Under Curve. Breast Diseases / classification. Breast Diseases / ultrasonography. Databases, Factual. Female. Humans. Principal Component Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 ISUOG.
  • (PMID = 16086435.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Devi PM, Singh LR, Gatphoh ED: Fibroadenoma with squamous metaplasia. Singapore Med J; 2007 Jul;48(7):682-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroadenoma is the most common benign breast tumour in adolescent and young women.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Fibroadenoma / pathology
  • [MeSH-minor] Adult. Female. Fibrocystic Breast Disease / complications. Fibrocystic Breast Disease / pathology. Humans. Metaplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609833.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


5. Navas Cañete A, Olcoz Monreal FJ, García Laborda E, Pérez Aznar JM: [Pseudoangiomatous stromal hyperplasia: magnetic resonance findings in two cases]. Radiologia; 2007 Jul-Aug;49(4):275-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hiperplasia pseudoangiomatosa estromal: hallazgos en resonancia magnética de dos casos.
  • Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast tumor of uncertain etiology, although marked hormonal influence clearly plays a role in this disease.
  • The differential diagnosis is important because this is an uncommon lesion that can simulate malignant lesions both at clinical and radiological examination, and even the histological results can be confusing.
  • [MeSH-major] Breast / pathology. Breast Diseases / diagnosis. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Pseudoangiomatous stromal hyperplasia.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594891.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Yang GZ, Li J, Ding HY: [Nipple adenoma: report of 18 cases with review of literatures]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):614-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinicopathological and immunohistochemical features, diagnosis and differential diagnosis of nipple adenoma of the breast.
  • RESULTS: The neoplasms were localized at nipples or under the areola of breast, adherent to the epidermis, mainly composed of dilated ducts in a tubular appearance associated with fibrotic matrix.
  • The tumor cells were crowding, lack of an uniform morphology and polarity with intact myoepithelial cells around the ducts.
  • CONCLUSIONS: Nipple adenoma is an infrequent type of benign breast neoplasm, presenting as sclerosing papilloma, papillomatosis or florid sclerosing adenosis.
  • A correct diagnosis is based on the peculiar location and morphology of the tumor, and immunohistochemistry is helpful in some cases.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Nipples / pathology
  • [MeSH-minor] Adult. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Keratin-5 / metabolism. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


7. Ying MG, Chen Q, Ye YB, Chen HJ, Chen X, Zheng HY, Wu F: [Application of serum proteomic mass spectrum analysis in breast cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):698-702
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of serum proteomic mass spectrum analysis in breast cancer].
  • OBJECTIVE: To analyze the characteristics of serum proteins mass spectra in healthy controls, benign breast tumors, and CA15-3 negative or CA15-3 positive breast cancer patients by surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS).
  • METHODS: Tissue samples of 113 cases of breast cancer (93 case of CA15-3 negative, 20 case of CA15-3 positive), 103 cases of benign breast tumor and 92 cases of healthy controls were examined and analyzed by SELDI and protein chip (CM10) techniques.
  • RESULTS: Twelve significantly different protein peaks were found in serum samples between breast cancer patients and healthy controls.
  • Eleven significantly different peaks were found between benign breast tumor patients and healthy controls.
  • By combined analysis of those three different protein mass spectra, the peak 15 952 was found to be significantly different between breast cancer group and healthy controls, and the peak 7985 was significantly different among breast cancer group, benign breast tumor group and health controls.
  • The blind test with the differential proteins for the serum samples of 93 cases of CA15-3 negative breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 80.6% and specificity was 91.7%.
  • The blind test in 20 cases of CA15-3 positive breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 75.0% and specificity was 91.7%.
  • Four significantly different protein peaks were found between the benign breast tumor patients and CA15-3 negative breast cancer patients.
  • CONCLUSION: Significantly different protein peaks can be screened out in breast cancer, benign breast tumor patients and healthy controls by SELDI-TOF-MS analysis.
  • [MeSH-major] Blood Proteins / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis. Proteomics / methods
  • [MeSH-minor] Adenoma / blood. Adenoma / diagnosis. Adenoma / metabolism. Adult. Aged. Biomarkers, Tumor / blood. Case-Control Studies. Female. Humans. Middle Aged. Mucin-1 / metabolism. Protein Array Analysis. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122387.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Mucin-1
  •  go-up   go-down


8. Ditsch N, Liebhardt S, Von Koch F, Lenhard M, Vogeser M, Spitzweg C, Gallwas J, Toth B: Thyroid function in breast cancer patients. Anticancer Res; 2010 May;30(5):1713-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid function in breast cancer patients.
  • BACKGROUND: Recent studies indicate a possible relationship between hypothyroidism and breast cancer in vivo.
  • In addition, oestrogen-like effects of thyroid hormones on breast cancer cell growth are seen in vitro.
  • Therefore, this study evaluated thyroid function in breast cancer patients, women with benign breast tumour and healthy controls.
  • PATIENTS AND METHODS: Breast cancer patients (n=65), women with carcinoma in situ (n=13) or benign breast tumour (n=27), and healthy controls (n=38) were included in the study.
  • RESULTS: fT3 and fT4 levels were highest in breast cancer patients, and differed significantly from controls (fT3 and fT4: p<0.001) as well as from patients with benign breast tumour (fT3: p=0.021; fT4: p=0.017).
  • With regard to TRAK antibodies, breast cancer patients showed the highest levels differing significantly from women with benign breast tumours (p=0.048).
  • CONCLUSION: Significant differences in fT3/fT4 as well as TRAK levels were observed among breast cancer patients, women with benign breast tumours and healthy controls.
  • [MeSH-major] Breast Neoplasms / physiopathology. Thyroid Gland / physiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592366.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Estrogens; 0 / Thyroid Hormones
  •  go-up   go-down


9. Liebhardt S, Ditsch N, Nieuwland R, Rank A, Jeschke U, Von Koch F, Friese K, Toth B: CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients. Anticancer Res; 2010 May;30(5):1707-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients.
  • BACKGROUND: This is the first prospective case-control study that evaluates the expression of tumour-specific antigens on circulating microparticles (MP) in breast cancer patients and in women with benign breast tumour.
  • MATERIALS AND METHODS: MP were determined by flow cytometry in patients with breast cancer (n=34; T1 (n=19) and T2 (n=15)) and women with benign breast tumour (n=19).
  • RESULTS: Patients with lymph node metastases (N1, n=9) showed significantly higher numbers of annexin V(+) MP (p=0.042), CD66(+) MP (p=0.045), BCRP1(+) MP (breast cancer resistance protein) (p=0.025) and Hsp27(+) MP (p=0.034) than controls.
  • CONCLUSION: Significant differences are present between breast cancer patients with lymph node metastases and controls concerning annexin V-, CD66-, BCRP1- and Hsp27-positive MP.
  • To specify the role of these MP subpopulations in breast cancer progression, further studies enrolling larger patient groups are part of ongoing research.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Breast Neoplasms / metabolism. Carcinoembryonic Antigen / metabolism. Cell-Derived Microparticles. HSP27 Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Receptor, ErbB-2 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592365.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Annexin A5; 0 / Carcinoembryonic Antigen; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Neoplasm Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


10. Ravindra S, Suguna BV: Cytomorphology of tubular adenoma breast--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):267-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of tubular adenoma breast--a case report.
  • Tubular adenoma a 'pure adenoma' is a benign neoplasm of breast presenting clinically like fibroadenoma.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fibroadenoma / pathology. Fibrocystic Breast Disease / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933735.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


11. Nalini R, Wilma Delphine Silvia CR, Uthappa S: Utility of blood DNA levels in diagnosis of breast cancer. J Cancer Res Ther; 2008 Apr-Jun;4(2):57-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of blood DNA levels in diagnosis of breast cancer.
  • BACKGROUND: Prognostic factors, including both histopathological and biochemical variables, influence the choice of modality and the course of therapy in breast cancer.
  • AIM: To find out if any correlation exists between blood DNA level and tumor stage, size and grade.
  • The cases comprised 25 patients with histopathologically confirmed malignant breast cancer, while 27 patients with benign breast tumors served as the control group.
  • Pearson's test was performed to find out the correlation between blood DNA levels and the TNM stage, tumor size and grade.
  • RESULTS: It was observed that blood DNA levels showed statistically significant correlation with the TNM stage, tumor size and grade.
  • CONCLUSION: The blood DNA level can be utilized as a noninvasive marker to assess tumor aggressiveness.
  • Thus, it can be useful as a prognostic marker and as a marker of tumor burden.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. DNA, Neoplasm / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasms / diagnosis. Neoplasms / surgery. Tumor Burden

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688119.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


12. Sandoval-Hermosillo F, Vázquez-Lara GA, Farias-Evangelista LD, Madrid-Venegas DC, Jiménez-Covarrubias MG, Ramírez-Villaseñor M, Delgado-Enciso I, Rodríguez-Hernández A, Montoya F, Montaño-Plasencia V, Vásquez C: [Comparing two diagnostic methods used for breast neoplasm in a cancer centre in Colima, Mexico]. Rev Salud Publica (Bogota); 2010 Jun;12(3):446-53
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparing two diagnostic methods used for breast neoplasm in a cancer centre in Colima, Mexico].
  • [Transliterated title] Comparación de dos métodos diagnósticos en tumores mamarios en un Centro de Cancerología de Colima, México.
  • OBJECTIVE: Determining the relationship between mammography neoplasm reports and histopathological diagnosis of neoplasms.
  • Patients were included who were attending the state cancerology centre (Centro Estatal de Cancerología) in Colima, Mexico.
  • Inclusion parameters were: females having mammography and BIRADS score of 1 or over; females having biopsy and histopathology diagnosis; females of all ages, all clinic stages having a complete clinic record.
  • RESULTS: No relationship between a BIRADS score classified as being benign (BIRADS I-II-III) or malign (BIRADS IV-V) was found with histopathological results (benign or malign) (p=0.0666).
  • CONCLUSIONS: I, III and V BIRADS scores had a relationship with histopathological diagnosis, while category II and IV BIRADS scores had no relationship.
  • [MeSH-major] Biopsy / statistics & numerical data. Breast Neoplasms / diagnosis. Cancer Care Facilities. Mammography / statistics & numerical data

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21311832.001).
  • [ISSN] 0124-0064
  • [Journal-full-title] Revista de salud pública (Bogotá, Colombia)
  • [ISO-abbreviation] Rev Salud Publica (Bogota)
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Colombia
  •  go-up   go-down


13. Harmer V: Breast cancer. Part 1: Awareness and common benign diseases. Br J Nurs; 2008 Aug 14-Sep 10;17(15):950-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer. Part 1: Awareness and common benign diseases.
  • Breast cancer is the most common cancer for women in the United Kingdom and topic on which there is much information.
  • This article discusses the principles behind breast awareness and breast health, detailing common benign breast diseases that cause disproportionate anxiety.
  • The NHS Breast Screening Programme is celebrating 20 years of screening this year, and in all randomized controlled trials of women aged 50 and over, mortality from breast cancer is reduced in those offered screening compared with unscreened controls (although the reduction is not statistically significant in all trials).
  • Once a breast cancer is diagnosed, the different characteristics and stage of the disease can be identified through histopathology and scans.
  • [MeSH-major] Breast Neoplasms / diagnosis
  • [MeSH-minor] Awareness. Diagnosis, Differential. England. Female. Humans. Mass Screening. Neoplasm Invasiveness. Referral and Consultation. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983015.001).
  • [ISSN] 0966-0461
  • [Journal-full-title] British journal of nursing (Mark Allen Publishing)
  • [ISO-abbreviation] Br J Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


14. Istvanic S, Fischer AH, Banner BF, Eaton DM, Larkin AC, Khan A: Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes. Diagn Cytopathol; 2007 May;35(5):263-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes.
  • Two major limitations of breast fine needle aspiration (FNA) compared with core needle biopsies (CNB) are the inability to determine whether a cancer is invasive and to classify proliferative lesions.
  • We studied 40 consecutive "rapid cell blocks" from breast FNAs with surgical pathology follow-up to test whether cell blocks can overcome these limitations.
  • Cell blocks from 12 of 14 benign breast FNAs showed sufficient cells to assign a histologic diagnosis of no hyperplasia (1 case, confirmed on follow-up) and usual hyperplasia (11 cases; confirmed in eight of 11 on follow-up).
  • Specific histologic diagnoses included intraductal papilloma (2 cases), and in situ lobular neoplasia (2 cases).
  • Cell blocks complement smears and monolayers and appear to overcome major limitations of breast FNA.
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Paraffin Embedding / methods
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / pathology. Carcinoma in Situ / classification. Carcinoma in Situ / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / pathology. Cell Proliferation. Female. Humans. Hyperplasia. Neoplasm Invasiveness. Papilloma, Intraductal / classification. Papilloma, Intraductal / pathology. Phyllodes Tumor / classification. Phyllodes Tumor / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427225.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ławicki S, Czygier M, Bedkowska E, Wojtukiewicz M, Szmitkowski M: Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors. Pol Arch Med Wewn; 2008 Sep;118(9):464-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
  • The direct production of this cytokine has been reported in tumor cell lines in vitro and in solid tumors in vivo.
  • OBJECTIVES: In the present study, the levels of M-CSF in patients with breast cancer and in those with a benign breast tumor were evaluated.
  • PATIENTS AND METHODS: The study group was made up of 70 patients with breast cancer and 20 patients with benign tumors and the control group of 30 healthy women.
  • RESULTS: Statistically higher levels of M-CSF and CA 15-3 were found in breast cancer patients as compared to the benign tumor and control groups.
  • CONCLUSIONS: The above data suggests that M-CSF might be useful in both diagnostics and differential diagnosis of benign tumors and breast cancer (except for the lowest degree of the clinical progression).
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846980.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


16. Ławicki S, Szmitkowski M, Wojtukiewicz M: The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin Chim Acta; 2006 Sep;371(1-2):112-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
  • BACKGROUND: In the present study, we investigated the plasma levels of M-CSF and commonly accepted tumor marker (antigen CA 15-3) in breast cancer patients in relation to the group with benign breast tumor and to the healthy controls.
  • Additionally, we compared the plasma level of M-CSF with the tumor stage of breast cancer and defined the diagnostic criteria: sensitivity, specificity, the positive and the negative predictive values.
  • METHODS: M-CSF and CA 15-3 were measured in 80 patients with breast cancer, 17 patients with benign breast tumor and in 30 healthy subjects.
  • RESULTS: There were statistically significant differences in the levels of circulating M-CSF and CA 15-3 in the breast cancer patients comparing to the group with benign breast tumor and to the control group.
  • The levels of M-CSF and CA 15-3 were also significantly higher in patients with more advanced tumor stage.
  • Statistically significant positive correlation was observed between the M-CSF and CA 15-3 levels.
  • The M-CSF and CA 15-3 diagnostic specificities were 95%.
  • We observed a higher range of the diagnostic sensitivity of M-CSF in more advanced breast tumor stage.
  • The M-CSF area under the ROC curve was larger (0.801) than the ROC area of CA 15-3 (0.785).
  • CONCLUSIONS: These results suggest that M-CSF is the good candidate for a breast cancer tumor marker.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood. Mucin-1 / blood
  • [MeSH-minor] Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. ROC Curve. Reagent Kits, Diagnostic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631152.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Reagent Kits, Diagnostic; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


17. Sandhya B, Babu V, Parthasarathy G, Kate V, Ananthakrishnan N, Krishnan R: Primary leiomyosarcoma of the breast: A case report and review of literature. Indian J Surg; 2010 Jul;72(Suppl 1):286-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the breast: A case report and review of literature.
  • Leiomyosarcomas of the breast are rare tumours.
  • We describe herein a case of primary leiomyosarcoma of the breast in a 54-year-old woman whose preoperative clinical and cytological findings indicated a benign breast tumour.
  • Histopathological examination of the mastectomy specimen suggested a diagnosis of leiomyosarcoma, which was subsequently confirmed by immunohistochemical analysis.
  • Primary leiomyosarcoma of the breast is very rare and is difficult to diagnose preoperatively as it needs immuno-histochemical staining.
  • It is necessary to excise the tumour with sufficient margins to prevent local recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1997;27(11):1082-5 [9413066.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):151-3 [11458280.001]
  • [Cites] Surg Today. 2002;32(8):716-9 [12181723.001]
  • [Cites] Arch Gynecol Obstet. 2003 Feb;267(4):233-5 [12592426.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):494-6 [14616945.001]
  • [Cites] Diagn Cytopathol. 2003 Sep;29(3):172-8 [12951688.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):783-6 [14526679.001]
  • (PMID = 23133273.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451846
  • [Keywords] NOTNLM ; Breast / Phyllodes Sandhya / Stromal tumours
  •  go-up   go-down


18. Harsløf SS, Andersen LM, Hoyer U, Christiansen JJ: [Breast cancer metastasis to the colon]. Ugeskr Laeger; 2010 Aug 23;172(34):2309-10
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast cancer metastasis to the colon].
  • She was diagnosed with metastases of a carcinoma to the colon; the immunohistochemical profile made lobular breast cancer the most likely primary tumour.
  • But despite thorough examination, such tumour was never found.
  • Twenty-two years earlier, the patient underwent surgery for a benign breast tumour.
  • The benign diagnosis was confirmed in new slides from the then removed tissue.
  • Metastases from breast cancer to the colon are rare, and a primary tumour is usually found.
  • In this case report, however, no primary tumour was found.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Colonic Neoplasms / secondary. Female. Humans. Neoplasms, Unknown Primary / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20727298.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


19. Cashell AW: Apocrine adenoma of the breast. W V Med J; 2008 Mar-Apr;104(2):16-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine adenoma of the breast.
  • A case of apocrine adenoma, a rare benign tumor of the breast is reported.
  • A left breast nodule from a 47-year-old female was found by mammography and excised.
  • The tumor was well circumscribed and composed of tightly packed tubules lined by cells with apocrine features.
  • Apocrine adenomas have been reported arising in a variety of sites including the breast, (1-5) perianal region, (6,7) eyelid, (8) and axilla. (9) Their appearance has similarities to the apocrine metaplasia commonly seen in fibrocystic change of the breast but they are well-circumscribed tumors with closely packed tubular and papillary structures.
  • They are not distinctive by mammography or physical examination and should be managed as any other breast mass.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Apocrine Glands / pathology. Breast Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18491794.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Liu C, Yan X, Zhang X, Yang W, Peng W, Shi D, Zhu P, Huang W, Yuan Q: Evaluation of x-ray diffraction enhanced imaging in the diagnosis of breast cancer. Phys Med Biol; 2007 Jan 21;52(2):419-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of x-ray diffraction enhanced imaging in the diagnosis of breast cancer.
  • The significance of the x-ray diffraction enhanced imaging (DEI) technique in the diagnosis of breast cancer and its feasibility in clinical medical imaging are evaluated.
  • Different massive specimens including normal breast tissues, benign breast tumour tissues and malignant breast tumour tissues are imaged with the DEI method.
  • The differences in DEI images and their rocking curves are evaluated for early diagnosis of breast cancers.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / radiography. Mammography / methods
  • [MeSH-minor] Absorption. Algorithms. Breast / pathology. Female. Humans. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Radiographic Image Enhancement. Radiographic Image Interpretation, Computer-Assisted. Scattering, Radiation. X-Ray Diffraction. X-Rays

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202624.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Lee JH, Kim SH, Kang BJ, Lee AW, Song BJ: Ultrasonographic features of benign adenomyoepithelioma of the breast. Korean J Radiol; 2010 Sep-Oct;11(5):522-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic features of benign adenomyoepithelioma of the breast.
  • OBJECTIVE: The purpose of this study was to evaluate the ultrasonographic features of benign adenomyoepithelioma of the breast.
  • MATERIALS AND METHODS: Between 2005 and 2009, five patients had histologically confirmed adenomyoepithelioma of the breast.
  • We retrospectively evaluated the ultrasonographic findings of the tumors in correlation with the pathology, and reviewed medical records.
  • The ultrasonographic assessments were classified as Breast Imaging Reporting and Data System (BI-RADS) category 4A, with low suspicion of malignancy in two cases, and as category 4B, with intermediate suspicion of malignancy in three cases.
  • The pathology revealed benign adenomyoepithelioma in all patients.
  • CONCLUSION: Benign adenomyoepitheliomas appear as solid or complex echoic masses with suspicious malignant ultrasonographic features, which may be associated with adjacent ductectasia.
  • Although adenomyoepithelioma is a rare breast tumor, awareness of its sonographic features will be helpful for the differential diagnosis from other tumors.
  • [MeSH-major] Adenomyoepithelioma / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):632-6 [10747327.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):488-90 [10834021.001]
  • [Cites] J Ultrasound Med. 2001 Sep;20(9):1021-4 [11549151.001]
  • [Cites] Breast J. 2002 Nov-Dec;8(6):383-4 [12390363.001]
  • [Cites] AJR Am J Roentgenol. 2003 Mar;180(3):799-803 [12591699.001]
  • [Cites] Breast. 2004 Aug;13(4):356-8 [15325675.001]
  • [Cites] Breast Cancer. 2007;14(4):429-33 [17986811.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1232-7 [2824328.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):554-68 [1709559.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):868-76 [1384377.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):386 [16848857.001]
  • [Cites] Breast J. 2007 Mar-Apr;13(2):203-4 [17319866.001]
  • [Cites] Acta Radiol. 2007 Feb;48(1):27-9 [17325921.001]
  • [Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]
  • (PMID = 20808695.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2930160
  • [Keywords] NOTNLM ; Adenomyoepithelioma / Breast / Ultrasonography
  •  go-up   go-down


22. Wauters CA, Sanders-Eras MC, de Kievit-van der Heijden IM, Wesseling P, Venderink DJ, van Dijk Azn R, van den Wildenberg F, Kooistra BW, Strobbe LJ: Modified core wash cytology (CWC), an asset in the diagnostic work-up of breast lesions. Eur J Surg Oncol; 2010 Oct;36(10):957-62
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified core wash cytology (CWC), an asset in the diagnostic work-up of breast lesions.
  • AIM: A quick and reliable preliminary diagnosis is essential in the management of a same-day breast clinic.
  • METHODS: From April 2008 to April 2009, biopsies were taken from lesions in the breast.
  • CWC was obtained from core needle biopsy (CNB) with a modified technique and classified into the categories: malignant, suspicious for malignancy, atypical, benign and inadequate.
  • RESULTS: CWC was obtained from 226 breast lesions.
  • In 167 of these cases subsequent resection of the lesion was performed revealing 149 carcinomas and 18 benign lesions.
  • Of the 149 malignant cases, 136 were considered as either malignant or suspicious for malignancy by CWC, 7 as atypical, 4 as benign and 2 as inadequate.
  • None of the 18 benign lesions were classified as suspicious or malignant on CWC.
  • CONCLUSIONS: In the vast majority of patients the modified CWC technique can provide a quick and reliable diagnosis of malignant breast lesions.
  • Furthermore, combining CWC with CNB histology can improve adequate, preoperative recognition of the malignant character of breast lesions.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Ambulatory Care / methods. Breast Diseases / diagnosis. Breast Diseases / pathology. Breast Diseases / surgery. Cohort Studies. Cytodiagnosis / methods. Diagnosis, Differential. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Netherlands. Preoperative Care / methods. Reproducibility of Results. Risk Assessment. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20708371.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Zhu Q, Hegde PU, Ricci A Jr, Kane M, Cronin EB, Ardeshirpour Y, Xu C, Aguirre A, Kurtzman SH, Deckers PJ, Tannenbaum SH: Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis. Radiology; 2010 Aug;256(2):367-78
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis.
  • PURPOSE: To investigate the potential role of optical tomography in the near-infrared (NIR) spectrum with ultrasonographic (US) localization as a means of differentiating early-stage cancers from benign lesions of the breast.
  • From this measurement, tumor angiogenesis was assessed on the basis of calculated total hemoglobin concentration (tHb) and was correlated with core biopsy results.
  • RESULTS: There were two in situ carcinomas (Tis), 35 T1 carcinomas, 24 T2-T4 carcinomas, and 114 benign lesions.
  • The mean maximum and mean average tHb of the benign group were 55.1 micromol/L +/- 22.7 and 39.1 micromol/L +/- 14.9, respectively.
  • Both mean maximum and mean average tHb levels were significantly higher in the malignant groups than they were in the benign group (P < .001).
  • The corresponding values for T2-T4 tumors were 75%, 93%, 69%, and 95%.
  • CONCLUSION: The angiogenesis (tHb) contrast imaged by using the NIR technique with US holds promise as an adjunct to mammography and US for distinguishing early-stage invasive breast cancers from benign lesions.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2004 Jan;230(1):42-8 [14695385.001]
  • [Cites] J Pathol. 2004 Oct;204(2):140-6 [15376259.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Radiology. 1995 Jul;196(1):123-34 [7784555.001]
  • [Cites] Arch Surg. 1996 Mar;131(3):301-8 [8611096.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Radiology. 2004 Dec;233(3):857-67 [15567802.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1152-60 [15568935.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):72-9 [15797295.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Appl Opt. 2005 Apr 10;44(11):2140-53 [15835360.001]
  • [Cites] Radiology. 2005 May;235(2):396-401 [15770039.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2429-49 [15901947.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2489-502 [15901950.001]
  • [Cites] Invest Radiol. 2005 Jun;40(6):328-35 [15905718.001]
  • [Cites] J Biomed Opt. 2005 Mar-Apr;10(2):024033 [15910106.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):229-37 [16034008.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] Radiology. 2005 Oct;237(1):57-66 [16183924.001]
  • [Cites] Breast Cancer Res. 2005;7(6):279-85 [16457705.001]
  • [Cites] Radiol Med. 2006 Apr;111(3):440-8 [16683089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8828-33 [16731633.001]
  • [Cites] Technol Cancer Res Treat. 2006 Aug;5(4):365-80 [16866567.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):180-7 [17154175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5474-9 [17875777.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):9-22 [17468951.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):539-44 [18267357.001]
  • [Cites] Acad Radiol. 2008 Jul;15(7):859-66 [18572121.001]
  • [Cites] Neoplasia. 2008 Oct;10(10):1028-40 [18813360.001]
  • [Cites] J Biomed Opt. 2008 Jul-Aug;13(4):044002 [19021330.001]
  • [Cites] Cancer. 2009 Apr 1;115(7):1363-80 [19197974.001]
  • [Cites] Radiology. 2009 Sep;252(3):665-72 [19567644.001]
  • [Cites] J Biomed Opt. 2009 Jul-Aug;14(4):044005 [19725717.001]
  • [Cites] Clin Radiol. 2000 Jan;55(1):40-4 [10650109.001]
  • [Cites] Radiology. 2000 Dec;217(3):841-8 [11110952.001]
  • [Cites] Ultrasound Med Biol. 2002 Jan;28(1):19-26 [11879948.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):347-54 [12082551.001]
  • [Cites] Opt Lett. 2003 Mar 1;28(5):337-9 [12659436.001]
  • [Cites] Neoplasia. 2003 Sep-Oct;5(5):379-88 [14670175.001]
  • (PMID = 20571122.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB002136
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2909434
  •  go-up   go-down


24. Farkash EA, Ferry JA, Harris NL, Hochberg EP, Takvorian RW, Zuckerman DS, Sohani AR: Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls. J Hematop; 2009;2(4):237-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls.
  • Breast involvement by lymphoma is uncommon and poses challenges in diagnosis.
  • Lymphomas may clinically, radiologically, and morphologically mimic both benign and neoplastic conditions.
  • We describe two cases of lymphoid malignancies predominantly involving the breast, both presenting diagnostic dilemmas.
  • The first case, ALK-negative anaplastic large-cell lymphoma involving a seroma associated with a breast implant, is an emerging clinicopathologic entity.
  • Anaplastic large-cell lymphoma has been identified in association with breast implants and seroma formation relatively recently.
  • The second case, hairy cell leukemia involving the breast and ipsilateral axillary sentinel lymph node, is, to our knowledge, the first reported case of hairy cell leukemia involving the breast at the time of diagnosis.
  • While a localized bone lesion was present at time of diagnosis, bone marrow involvement was relatively mild in comparison to that seen in the breast and lymph node.
  • In the first case, lymphoma occurred in a clinical setting where malignancy was unsuspected, highlighting the importance of careful morphologic evaluation of paucicellular samples, as well as awareness of rare clinicopathologic entities, in avoiding a misdiagnosis of a benign inflammatory infiltrate.
  • In the second case, the lymphoid neoplasm exhibited classic morphologic and immunophenotypic features, but presented at an unusual site of involvement.
  • Knowledge of the patient's concurrent diagnosis of hairy cell leukemia involving the bone marrow and bone helped avoid a misdiagnosis of carcinoma rather than lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Medica (Hradec Kralove). 2003;46(4):175-7 [14965169.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):397-404 [12764549.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Oct;20(5):1065-73 [16990107.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1511-20 [18704988.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • [Cites] Cancer. 1979 Apr;43(4):1339-49 [445334.001]
  • [Cites] Br J Cancer. 1989 Oct;60(4):605-9 [2803932.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1280-4 [3411340.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Ann Intern Med. 1973 Jan;78(1):113-8 [4565899.001]
  • [Cites] Cancer. 1974 May;33(5):1399-410 [4823484.001]
  • [Cites] Semin Oncol. 1984 Dec;11(4):370-80 [6505704.001]
  • [Cites] Plast Reconstr Surg. 1994 Oct;94(5):628-33; discussion 634-6 [7938285.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):505-7 [8604821.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):819-27 [11075871.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • (PMID = 20309431.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2798933
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Anaplastic lymphoma kinase / Breast / Breast implant / Hairy cell leukemia / Primary breast lymphoma / Seroma / T-cell neoplasm
  •  go-up   go-down


25. Rinaldi P, Giuliani M, Belli P, Costantini M, Romani M, Distefano D, Bufi E, Mulè A, Magno S, Masetti R, Bonomo L: DWI in breast MRI: role of ADC value to determine diagnosis between recurrent tumor and surgical scar in operated patients. Eur J Radiol; 2010 Aug;75(2):e114-23
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DWI in breast MRI: role of ADC value to determine diagnosis between recurrent tumor and surgical scar in operated patients.
  • INTRODUCTION: Purpose of our study is to evaluate the role of the apparent diffusion coefficient (ADC) in the diagnosis of recurrent tumor on the scar in patients operated for breast cancer.
  • Assess, therefore, the weight of diagnostic diffusion echo-planar sequence, in association with the morphological and dynamic sequences in the diagnosis of tumor recurrence versus surgical scar.
  • MATERIALS AND METHODS: From September 2007 to March 2009, 72 patients operated for breast cancer with suspected recurrence on the scar were consecutively subjected to magnetic resonance imaging (MRI), including use of a diffusion sequence.
  • RESULTS: 26 cases were positive/doubtful at MRI and then subjected to histological typing: of these recurrences were 20 and benign were 6.
  • CONCLUSIONS: ADC value can be a specific parameter in differential diagnosis between recurrence and scar.
  • The diffusion sequence, in association with the morphological and dynamic sequences, can be considered a promising tool for the surgical indication in suspected recurrence of breast cancer.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Cicatrix / diagnosis. Diffusion Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20172677.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


26. Al-Khawari H, Kovacs A, Athyal R, Al-Manfouhi H, Fayaz MS, Madda JP: Breast magnetic resonance imaging: initial experience in Kuwait. Med Princ Pract; 2009;18(2):143-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast magnetic resonance imaging: initial experience in Kuwait.
  • OBJECTIVE: To report our initial experience of breast magnetic resonance imaging (MRI) in Kuwait in order to identify and characterize breast lesions.
  • SUBJECTS AND METHODS: In 58 patients ranging in age from 25 to 64 years, breast MRI was performed as a problem-solving tool (29); for suspicious local relapse of the treated breast (6); to search for a primary breast cancer in patients with metastatic axillary lymph nodes (5); for local staging of breast cancer (5); breast implants (6); screening in high-risk patients (3), and differentiation between inflammation and inflammatory carcinoma (4).
  • RESULTS: Seventy breast lesions (25 malignant, 38 benign and 7 lesions detected by MRI only) were identified in the 58 patients.
  • The sensitivity, specificity, and positive and negative predictive values of MRI in diagnosing malignant breast lesions were 96, 67, 71 and 95%, respectively, while the accuracy was 80%.
  • [MeSH-major] Breast. Breast Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Kuwait. Magnetic Resonance Imaging. Mass Screening / methods. Middle Aged. Neoplasm Staging / methods. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19204434.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


27. Martínez-Galán J, Torres B, Del Moral R, Muñoz-Gámez JA, Martín-Oliva D, Villalobos M, Núñez MI, Luna Jde D, Oliver FJ, Ruiz de Almodóvar JM: Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther; 2008 Jun;7(6):958-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy.
  • The aim of the present study was to investigate the association between gene hypermethylation and main clinicopathological features of breast cancer, including diagnosis and treatment response.
  • A sensitive SYBR green methylation-specific PCR technique was used to analyze the utility of circulating DNA with CpG island hypermethylation of ESR1, APC, RARB, 14-3-3-sigma and E-cad gene promoter regions as breast cancer biomarkers.
  • Analyses were conducted of preoperative sera from 106 women with breast cancer, 34 with benign breast disease and 74 with no evidence of breast disease and of post-treatment sera from 60 of the breast cancer patients.
  • Mean serum values of methylated ESR1 and 14-3-3-sigma gene promoters significantly differed between breast cancer patients and healthy controls (p = 0.0112 for ESR1 and p = 0.0047 for 14-3-3-sigma).
  • When their results were combined, it was found that hypermethylation of these two genes differentiated between breast cancer patients and healthy controls (p < 0.0001) with a sensitivity of 81% (95% confidence interval: 72-88%) and specificity of 88% (95% CI: 78-94%).
  • Presence of methylated ESR1 in serum of breast cancer patients was associated with the ER negative phenotype (p = 0.0179).
  • Serum hypermethylation at ESR1 and 14-3-3-sigma loci was observed in cancer patients, in situ carcinoma and benign breast disease.
  • Preliminary clinical applications of this approach have revealed several shortcomings, including a frequent presence of methylated 14-3-3-sigma in sera from women with breast benign disease.
  • These findings cast some doubts on the utility for early cancer diagnosis of highly sensitive techniques to identify hypermethylation of specific gene promoters in DNA extracted from serum.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Estrogen Receptor alpha / metabolism. Exonucleases / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] 14-3-3 Proteins. Case-Control Studies. DNA Methylation. DNA, Neoplasm / metabolism. Disease Progression. Exoribonucleases. Female. Humans. Phenotype. Polymerase Chain Reaction. Promoter Regions, Genetic. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379196.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Estrogen Receptor alpha; 0 / Neoplasm Proteins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


28. Cyran CC, Fu Y, Raatschen HJ, Rogut V, Chaopathomkul B, Shames DM, Wendland MF, Yeh BM, Brasch RC: New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. J Magn Reson Imaging; 2008 Mar;27(3):581-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues.
  • MATERIALS AND METHODS: Thirty-two athymic rats with human breast cancer xenografts (MDA-MB-435) were imaged by dynamic MRI following enhancement with one of three new (Gd-DOTA)-conjugated PEG-core dendrimer contrast agents (effective molecular weights 161 to 323 kDa).
  • 100 cm(3)) and tumor fractional plasma volumes (%) based on a two-compartment kinetic model were performed for skeletal muscle and tumors.
  • RESULTS: The largest PEG-core contrast agent, PEG(20,000)-Gen4-(Gd-DOTA), leaked in breast tumors (K(PS) = 50 +/- 23 microL/min .
  • PEG(12,000)-Gen4-(Gd-DOTA) leaked in tumors and in normal muscle (K(PS) = 51 +/- 26 and K(PS) = 21 +/- 18 microL/min .
  • CONCLUSION: MRI assays of vascular endothelial leakiness using new PEG-core, (Gd-DOTA)-conjugated macromolecular contrast agents proved applicable for the differentiation of human breast cancer from normal soft tissue.
  • [MeSH-major] Contrast Media. Gadolinium. Heterocyclic Compounds. Magnetic Resonance Imaging. Neoplasms, Experimental / diagnosis. Organometallic Compounds
  • [MeSH-minor] Animals. Breast Neoplasms / diagnosis. Endothelium, Vascular. Female. Humans. Neoplasm Transplantation. Rats. Rats, Nude. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219614.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 082923; United States / NCI NIH HHS / CA / R01 CA 103850
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Heterocyclic Compounds; 0 / Organometallic Compounds; 92923-44-9 / gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


29. Thriveni K, Deshmane V, Bapsy PP, Krishnamoorthy L, Ramaswamy G: Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. Indian J Med Res; 2007 Feb;125(2):137-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients.
  • BACKGROUND & OBJECTIVE: In breast cancer, the HER-2/neu gene is amplified in 20-30 per cent of cases.
  • Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and thus might help in management of the disease.
  • The present study was therefore to estimate the serum HER-2/neu levels in breast cancer patients and associate with other prognostic factors.
  • METHODS: Serum HER-2/neu levels were studied in 207 patients with cancer breast, 15 benign breast diseases (BBD) and 175 age-matched healthy controls.
  • INTERPRETATION & CONCLUSION: HER-2/neu serum test could be done more frequently in women with breast cancer irrespective of the hormone receptor status, to suggest modifications in systemic adjuvant therapy, including possibly the use of Herceptin.
  • [MeSH-major] Breast Neoplasms / diagnosis. Receptor, ErbB-2 / blood
  • [MeSH-minor] Age Factors. Female. Gene Expression Regulation, Neoplastic. Humans. India. Logistic Models. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431282.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


30. Acs G, Dumoff KL, Solin LJ, Pasha T, Xu X, Zhang PJ: Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma. Am J Surg Pathol; 2007 Jan;31(1):129-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma.
  • Retraction artifact resulting in clear spaces around tumor cell nests is frequently seen in histologic material and may present difficulty in their differentiation from lymphovascular invasion.
  • We noticed that retraction artifact seemed to be more common around groups of breast cancer cells compared with benign acini, and when extensively present, metastasis to axillary lymph nodes was often seen.
  • Thus, we performed a study of 304 cases of stage pT1 and pT2 breast carcinomas to test our hypothesis that extensive retraction artifact in tumors correlates with lymphatic spread and outcome.
  • Tumors were evaluated to determine the presence and extent of retraction artifact around tumor cell nests and the presence of lymphatic invasion.
  • The extent of retraction artifact in tumors was correlated with clinicopathologic tumor features and patient outcome.
  • The extent of retraction artifact showed a significant correlation with tumor size, histologic type, histologic grade, presence of lymphovascular invasion, and nodal metastasis.
  • We propose that the apparent retraction of the stroma from cells of invasive breast carcinoma on routine histologic sections is not a phenomenon merely due to inadequate fixation as currently believed.
  • Rather, it likely signifies important biologic changes that alter tumor-stromal interactions and contribute to lymphatic spread and tumor progression.
  • [MeSH-major] Artifacts. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Histocytological Preparation Techniques. Lymph Nodes / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Early Diagnosis. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. ROC Curve. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197929.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


31. Uygun K, Kocak Z, Altaner S, Cicin I, Tokatli F, Uzal C: Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer. Yonsei Med J; 2006 Aug 31;47(4):578-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer.
  • Although the lung, liver, or bones are the most common location for distant metastases in breast cancer patients, metastases to the intestinal tract are very rarely recognized in the clinic.
  • We will present an unusual case of colonic metastasis from a carcinoma of the breast that mimics a primary intestinal cancer, along with a through review of English language medical literature.
  • Despite the fact that isolated gastrointestinal (GI) metastases are very rare and much less common than benign disease processes or second primaries of the intestinal tract in patients with a history of breast cancer, metastatic disease should be given consideration whenever a patient experiences GI symptoms.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):3014-6 [11051411.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):463-4 [12099661.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Surg Oncol. 1979;11(3):193-205 [459515.001]
  • [Cites] Dis Colon Rectum. 1988 May;31(5):401-2 [3366041.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] Am J Clin Oncol. 1992 Aug;15(4):365-9 [1514536.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Med Klin (Munich). 1992 Dec 15;87(12):631-6 [1287424.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):681-2 [10919011.001]
  • (PMID = 16941751.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687742
  •  go-up   go-down


32. Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M, Ishikita T, Koyama K: PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol; 2006 Aug;11(4):286-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
  • FDG-PET provides information that is not obtainable with other imaging modalities, and is very effective in the diagnosis and management of patients with various types of cancers.
  • PET and/or PET/CT using FDG is clinically useful in the detection of cancer, the differentiation of malignant and benign lesions, the staging of cancer before therapy, and the assessment of cancer therapy, as well as for determining the recurrence after therapy of most cancers, including lung cancer, gastrointestinal cancer, breast cancer, and malignant lymphoma.
  • PET/CT has become the new standard approach to imaging in the diagnosis and management of many cancer patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / diagnosis. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, Emission-Computed / methods
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / radionuclide imaging. Carcinoma / diagnosis. Carcinoma / radionuclide imaging. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / radionuclide imaging. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / radionuclide imaging. Lymphoma / diagnosis. Lymphoma / radionuclide imaging. Neoplasm Staging / methods. Whole Body Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16937302.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 51
  •  go-up   go-down


33. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • However, its expression in other tumour types is not fully explored.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


34. Ciatto S, Houssami N, Ambrogetti D, Bianchi S, Bonardi R, Brancato B, Catarzi S, Risso GG: Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies. Breast Cancer Res Treat; 2007 Mar;101(3):291-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies.
  • Breast core needle biopsy (CNB) is used for sampling breast lesions in both the screening and diagnostic context.
  • We present the accuracy of breast CNB from a consecutive series of 4035 core biopsies, using methods that minimise selection and verification bias.
  • False negatives occurred in 4.4% (3.4-5.4%) of cases, and where core histology was benign but discordant with (suspicious) imaging and/or clinical findings the likelihood of malignancy was 33.1% (18.5-47.7%), emphasising the importance of correlating all test information in breast diagnosis.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Breast Diseases / pathology. Breast Diseases / ultrasonography. Diagnosis, Differential. Follow-Up Studies. Humans. Hyperplasia / diagnosis. Hyperplasia / pathology. Neoplasm Invasiveness. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Stereotaxic Techniques. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16823506.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


35. Tang HW, Luo MN, Li T, Pan L: Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope. Anal Sci; 2006 May;22(5):701-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope.
  • In this study, the high potential value of the microscope in biomedical analysis has been demonstrated by using it to evaluate the malignancy degree of thirty cases of human breast tumors based on the measurements of cellular DNA contents, with conclusions highly accordant with pathological diagnosis.
  • The microscope was also successfully applied to cellular morphological analysis, and it was demonstrated that a significant linear relationship exists between tumor nuclear DNA contents and the nuclear area, and malignant and benign tumors are significantly different in both DNA contents and nuclear area.
  • [MeSH-major] Breast Neoplasms / pathology. DNA, Neoplasm / analysis
  • [MeSH-minor] Female. Humans. Image Cytometry. Microscopy, Fluorescence. Ploidies. Sensitivity and Specificity. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770048.001).
  • [ISSN] 0910-6340
  • [Journal-full-title] Analytical sciences : the international journal of the Japan Society for Analytical Chemistry
  • [ISO-abbreviation] Anal Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


36. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol; 2010 Jun;19(2):92-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
  • As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin.
  • Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated.
  • Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P).
  • In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated.
  • In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively.
  • A statistically significant correlation between hMAM and malignancy was found in the entire population (DOR=14.68, P<0.001) and in the male (DOR=15.00, P<0.001) or female (DOR=12.77, P<0.001) groups. hMAM RT-PCR increased the diagnostic rate of malignant PEs as it allowed us to detect as malignant 32.1% of cytologically negative PEs.
  • In female patients the positivity of hMAM indicated with higher probability (50.8%) the origin of PEs from breast cancer but lower probability from LC (17%), MM (9.4%), or other cancers (15.1%), whereas in male patients it indicated with similar probability (about 40%) the origin from LC or MM.
  • Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Neoplasm Proteins / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Male. Mammaglobin A. Middle Aged. United States. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502186.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


37. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P, Benign Breast Diseases Study Group: Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci U S A; 2008 Sep 23;105(38):14533-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
  • Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
  • Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
  • Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Fibroadenoma / genetics. Fibroadenoma / metabolism. Mutation, Missense. Receptors, Prolactin / genetics. Receptors, Prolactin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):665-71 [14696092.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4056-66 [16809439.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] Acta Obstet Gynecol Scand. 1987;66(6):483-8 [3321867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4031-5 [7537382.001]
  • [Cites] Mol Endocrinol. 1996 Jan;10(1):45-56 [8838144.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29707-14 [8939904.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):667-74 [9467590.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81 [17024156.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):989-1008 [17138649.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):841-4 [17299388.001]
  • [Cites] BMC Med Genet. 2007;8:72 [18053149.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4664-74 [12879011.001]
  • [Cites] Front Biosci. 2000 Mar 1;5:D343-52 [10704433.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):808-15 [10966654.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3826-32 [11502819.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):R1-4 [11572805.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):49-66 [12160086.001]
  • [Cites] Endocrine. 2003 Feb-Mar;20(1-2):177-90 [12668884.001]
  • [Cites] Recent Prog Horm Res. 2003;58:297-323 [12795425.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):35988-99 [12824168.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):225-68 [9626554.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10024-34 [10187780.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):275-85 [16034013.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):555-62 [16278261.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1513-9 [16434456.001]
  • [Cites] J Endocrinol. 2006 Aug;190(2):271-85 [16899561.001]
  • [Cites] Biol Reprod. 2004 Mar;70(3):718-28 [14613905.001]
  • (PMID = 18779591.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Receptors, Prolactin; 0 / STAT5 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • [Other-IDs] NLM/ PMC2567233
  • [Investigator] Bachelot A; Belaroussi B; Bensimhon J; Berdah J; Blin MJ; Boudinet A; Brethon B; Bricaire C; Caby J; Caillaud G; Carel JC; Chabbert-Buffet N; Charitanski H; Chretien C; Clough K; Courtillot C; Delattre G; Denys I; Desthieux-Ngo K; Detoeuf M; Dhainault C; Duflos C; Fiori O; Genestie C; Gibaud G; Gompel A; Gracia C; Grimard A; Hofman C; Hofman H; Kuttenn F; Laki F; Lanty C; Lefranc JP; Le Frere-Belda MA; Leger D; Martinez F; May A; Meng L; Nos C; Pelletier D; Perrin A; Plu-Bureau G; Raccah-Tebbeca B; Saiovici JC; Salmon R; Sibout M; Sigal-Zafrani B; Thalabard JC; Thibaud E; Thoury A; Touraine P; Triana-Rabi KB; Uzan S; Viriot J; Yacoub S
  •  go-up   go-down


38. Oba M, Sasaki M, Ii T, Hoso M, Ajisaka H, Matsuki N, Miwa K: A case of lymphocytic mastopathy requiring differential diagnosis from primary breast lymphoma. Breast Cancer; 2009;16(2):141-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of lymphocytic mastopathy requiring differential diagnosis from primary breast lymphoma.
  • Lymphocytic mastopathy is a benign breast disease characterized by dense fibrosis, lobular atrophy, and aggregates of lymphocytes in a periductal and perivascular distribution.
  • Here, we report a case of the disease clinically and radiologically mimicking primary breast neoplasms.
  • The patient was a 50-year-old woman without diabetes who presented with two firm lumps in her right breast.
  • Breast imaging findings from mammography, ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI), respectively, revealed an abnormal appearance suspicious of malignancy.
  • A core-needle biopsy specimen showed atypical accumulation of lymphoid cells, which was not easy to differentiate from primary breast lymphomas.
  • In our case, it was difficult to distinguish this entity from breast cancer or low-grade B-cell lymphoma without surgical biopsy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphocytes / pathology. Lymphoma / diagnosis. Mastitis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Tomography, X-Ray Computed. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769994.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


39. Moore A, Hendon A, Hester M, Samayoa L: Secondary angiosarcoma of the breast: can imaging findings aid in the diagnosis? Breast J; 2008 May-Jun;14(3):293-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary angiosarcoma of the breast: can imaging findings aid in the diagnosis?
  • Secondary angiosarcomas, although rare, are aggressive tumors that can develop in breast tissue that has undergone prior radiation therapy.
  • We present three cases of secondary angiosarcoma of the breast in the setting of prior breast irradiation.
  • Imaging findings include cutaneous nodules and progressive skin or trabecular thickening in an area of the breast separate from the patient's original breast carcinoma.
  • These imaging findings may enable the radiologist to suggest this diagnosis, even when the clinical presentation is more benign.
  • [MeSH-major] Breast Neoplasms / diagnosis. Hemangiosarcoma / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Radiation-Induced / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18476885.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Dillon MF, Quinn CM, McDermott EW, O'Doherty A, O'Higgins N, Hill AD: Needle core biopsy in the diagnosis of phyllodes neoplasm. Surgery; 2006 Nov;140(5):779-84
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle core biopsy in the diagnosis of phyllodes neoplasm.
  • BACKGROUND: Accurate identification of phyllodes neoplasms without surgical intervention is difficult, reducing the ability to manage "benign" lumps non-operatively and impacting on the open benign biopsy rate.
  • Needle core biopsy is considered to be a highly accurate technique in the diagnosis of breast carcinoma.
  • Its accuracy in the diagnosis of phyllodes neoplasm has not been established.
  • RESULTS: Twenty-three patients had phyllodes neoplasm on excisional biopsy with prior core biopsy findings as follows: phyllodes neoplasm (n=2), "equivocal" for phyllodes neoplasm (n=12), fibroadenoma (n=3), benign (n=6).
  • The false negative rate for phyllodes neoplasm was therefore 39% (n=9/23).
  • Of the total biopsy series, 35 patients had a core biopsy suggesting the possibility of phyllodes neoplasm.
  • Of these, 32% (n=11) were found to be phyllodes neoplasm on excision, 3% (n=1) phyllodes neoplasm with breast carcinoma, 6% (n=2) breast carcinoma, and 3% (n=1) sarcoma.
  • When a preference for phyllodes neoplasm (n=4) was stated on the equivocal core biopsies, excision correlated with the stated preference; this correlation also occurred in 90% (n=9/10) of core biopsies where fibroadenoma was favored.
  • CONCLUSIONS: Needle core biopsy rarely produces a definite preoperative diagnosis of phyllodes neoplasm.
  • A diagnosis of fibroadenoma or equivocal phyllodes neoplasm on core biopsy should not prevent excision if clinical suspicion remains.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Diagnostic Errors. Phyllodes Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084721.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Elusoji SO, Famodu AA, Aigbe A, Osime C, Iribhogbe PE, Oludiran O, Egwakhide E, Elusoji C, Oluedo A: Haemorheological changes in African breast cancer patients. Afr J Reprod Health; 2008 Apr;12(1):84-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haemorheological changes in African breast cancer patients.
  • Packed cell volume (PCV), heamoglobin (Hb), relative plasma viscosity (RPV) and plasma Fibrinogen concentration (PFC) were measured in 50 healthy control women, 50 age-matched women with breast cancer, and 10 women with histophathologically proven benign breast tumour.
  • There were significant differences between the controls and breast cancer patients in all the parameters measured (p < 0.05).
  • Since increased fibrinogen may give rise to increase fibrin formation which has been asserted as an independent cardiovascular risk factor for thromb-oembolic complications, African patients with breast cancer may well be predisposed to thrombotic complications during illness.
  • The theological assessment may offer valuable benefit for the management and early diagnosis of breast cancer in African women.
  • [MeSH-major] Blood Viscosity. Breast Neoplasms / blood. Fibrinogen / analysis. Hematocrit. Hemorheology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20695159.001).
  • [ISSN] 1118-4841
  • [Journal-full-title] African journal of reproductive health
  • [ISO-abbreviation] Afr J Reprod Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 9001-32-5 / Fibrinogen
  •  go-up   go-down


42. Grenier J, Delbaldo C, Zelek L, Piedbois P: [Phyllodes tumors and breast sarcomas: a review]. Bull Cancer; 2010 Oct;97(10):1197-207
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumors and breast sarcomas: a review].
  • [Transliterated title] Tumeurs phyllodes et sarcomes du sein: mise au point.
  • Phyllodes tumors and sarcomas of the breast are non-epithelial tumors of the breast.
  • Phyllodes tumors are benign tumors, tumors of intermediate malignancy or malignant tumors.
  • The differential diagnosis with a very proliferant fibroadenoma may be difficult.
  • Radiotherapy is recommended in case of high-grade tumor and after conservativetreatment.
  • Breast sarcomas are even rarer.
  • All histological types exist with a predominance of histiofibrocytome type tumors.
  • Grade, involved margins and sometimes tumor necrosis are major prognostics factors.
  • In some situations, a conservative treatment can be discussed, based on tumor size, grade and volume of the breast.
  • Locoregional radiotherapy is often proposed for tumors over 5 cm and/or of high grade.
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology. Sarcoma / pathology
  • [MeSH-minor] Female. Hemangiosarcoma / pathology. Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855241.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


43. Madjar H, Becker S, Doubek K, Horchler T, Mendoza M, Moisidis-Tesch C, Näther B, Niebling K, Pröls U, Schardt AR, Ulrich S, Zahn U: [Impact of breast ultrasound screening in gynecological practice]. Ultraschall Med; 2010 Jun;31(3):289-95
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of breast ultrasound screening in gynecological practice].
  • [Transliterated title] Bedeutung der Mammasonografie für die Brustkrebsfrüherkennung in der gynäkologischen Praxis.
  • PURPOSE: To define the value of whole breast ultrasound for breast cancer detection in primary women's health care in gynecological routing practice.
  • MATERIALS AND METHODS: Among women who were operated at the breast center of the German Diagnostic Clinic (DKD) in the year 2007, we selected different indications for the examinations which were relevant for the detection of breast lesions.
  • RESULTS: Twenty-one of 86 breast cancers (24 %) which were treated at the DKD in the year 2007 were detected only because of an individual ultrasound screening examination.
  • In this group of patients, only 8 benign lesions detected by ultrasound were operated.
  • This corresponds to a ratio of benign vs. malignant operations of 0.4 to 1, which is far superior to the recommendations of international guidelines for quality assurance.
  • CONCLUSION: Our results show that ultrasound screening considerably increases the detection of early breast cancers without increasing the rate of unnecessary biopsies.
  • This should encourage gynecologists to learn and perform systematic breast ultrasound examinations and to increase their own performance by continuous training.
  • We can expect that additional studies will prove breast ultrasound to be a powerful method for improving breast cancer detection.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Carcinoma, Lobular / ultrasonography. Mass Screening. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Breast Diseases / pathology. Breast Diseases / surgery. Breast Diseases / ultrasonography. Early Diagnosis. Female. Germany. Humans. Male. Mammography. Middle Aged. Neoplasm Staging. Quality Assurance, Health Care. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20408119.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Cheng TY, Chen CM, Lee MY, Lin KJ, Hung CF, Yang PS, Yu BL, Yang CE, Tsai TJ, Lin CW: Risk factors associated with conversion from nonmalignant to malignant diagnosis after surgical excision of breast papillary lesions. Ann Surg Oncol; 2009 Dec;16(12):3375-9
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors associated with conversion from nonmalignant to malignant diagnosis after surgical excision of breast papillary lesions.
  • PURPOSE: Management of papillary lesions of the breast identified during preoperative tissue diagnosis remains controversial.
  • This study was designed to analyze the clinical factors associated with under-diagnosis of malignancy in breast papillary lesions.
  • METHODS: Patients with a preoperative tissue diagnosis of benign or atypical papillary lesions, who received surgical excision between 1991 and 2005, were identified.
  • Age of diagnosis, family history of breast cancer, presentation of nipple discharge, palpable mass, mammogram grading, size of lesion, and final pathological diagnosis were analyzed.
  • Tissue sections were reviewed to confirm the diagnosis of malignancy and reasons of discrepancy.
  • Patients aged 45 years or older and atypical lesions according to fine needle aspiration cytology (FNAC) or core needle biopsy (CNB) were associated with higher risk for postoperative malignant diagnosis with P values of 0.0008 and < 0.0001, respectively.
  • Pathology review of 19 lesions with malignancy revealed that reasons for preoperative nonmalignant diagnosis were borderline lesions in nine (47.3%), sampling problem in six (31.5%), interpretation error in three (15.7%) and uninterpretable sample in one (5.2%).
  • CONCLUSIONS: In this cohort, 9.21% of preoperative nonmalignant papillary lesions were converted to malignant diagnosis after surgery.
  • Surgical excision should be considered for papillary lesions of breast, especially for patients with the identified risk factors.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Diseases / surgery. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Precancerous Conditions / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19641969.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Tse GM, Tan PH, Moriya T: The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol; 2009 May;62(5):407-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
  • Papillary lesions of the breast represent a heterogeneous group with differing biological behaviour.
  • Correct diagnosis is crucial but may be difficult, as many benign and malignant papillary lesions have similar appearances.
  • A panel of CK5/6, p63 and neuroendocrine markers can be useful in the diagnostic investigation of problematic papillary lesions of the breast.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Papilloma / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Diagnosis, Differential. Female. Humans. Keratins / analysis. Neoplasm Proteins / analysis. Nerve Tissue Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126567.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 33
  •  go-up   go-down


46. Turnbull LW: Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed; 2009 Jan;22(1):28-39
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer.
  • Dynamic contrast-enhanced MRI (DCE-MRI) is an evolving tool for determining breast disease, which benefits from the move to imaging at 3 T.
  • It has major capabilities for the diagnosis, detection and monitoring of malignancy.
  • However, there are also a number of limitations, including the overlap in enhancement patterns between malignant and benign disease, the failure to resolve microscopic disease particularly in the neoadjuvant setting, and the inconsistent predictive value of the enhancement pattern for clinical outcome.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / therapy. Contrast Media. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Carcinoma, Ductal, Breast / diagnosis. Female. Humans. Mass Screening. Neoplasm, Residual / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654999.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 71
  •  go-up   go-down


47. Jabłonowska E, Kołacinska A, Kuydowicz J, Przybyłowska K, Jabłonowski Z: Interleukin-6 and the IL-6 (-174) C/G polymorphism in breast pathologies and in HIV-infected patients. Arch Med Sci; 2010 Dec;6(6):860-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6 and the IL-6 (-174) C/G polymorphism in breast pathologies and in HIV-infected patients.
  • INTRODUCTION: Breast cancer and acquired immunodeficiency syndrome (AIDS) are key issues for modern medicine.
  • MATERIAL AND METHODS: Thirty-one women with benign breast tumours, 42 breast cancer patients and 40 HIV-infected females were enrolled in the study.
  • RESULTS: Serum IL-6 in patients with benign breast tumours was significantly lower than in females with breast cancer (p = 0.017) and HIV-infected women (p = 0.032).
  • We did not find statistically significant differences in serum IL-6 level between females with breast cancer and HIV-infected women (p = 0.749).
  • Comparing the distribution of genotypes and frequency of the IL-6 (-174) C/G polymorphism between the three study groups - breast cancer patients, patients with benign breast tumours, and HIV-infected patients - we did not find any statistically significant differences.
  • CONCLUSIONS: IL-6 can play an important role in pathogenesis of breast cancer and HIV infection and its level is higher than in the control group irrespective of distribution of genotypes and frequency of the IL-6 (-174) C/G polymorphism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22427758.001).
  • [ISSN] 1896-9151
  • [Journal-full-title] Archives of medical science : AMS
  • [ISO-abbreviation] Arch Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3302696
  • [Keywords] NOTNLM ; HIV / breast diseases / interleukin-6 / polymorphism
  •  go-up   go-down


48. Looi LM, Cheah PL, Ng MH, Yip CH, Mun KS, Rahman NA: Comparison of telomere length and telomerase activation between breast fibroadenoma and infiltrating ductal carcinoma in Malaysian women. Asian Pac J Cancer Prev; 2010;11(3):713-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of telomere length and telomerase activation between breast fibroadenoma and infiltrating ductal carcinoma in Malaysian women.
  • A study was initiated to explore possible differences in handling telomere attrition in the most common lignant and benign tumours of the breast in Malaysian women.
  • Infiltrating ductal carcinoma (IDC) and fibroadenoma (FA) represented the malignant and benign prototypes respectively.
  • 29 IDC, 28 FA and 22 benign non-lesional control (BNL) breast tissue samples were analysed for telomerase activation using a Telomerase PCR ELISA kit (Boehringer Mannheim).
  • The findings imply that telomere attrition and telomerase activation differ between malignant and benign tumours of the breast and may be important for targeted therapy.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Fibroadenoma / pathology. Telomerase / metabolism. Telomere / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Polymerase Chain Reaction. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039041.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


49. Queiroga FL, Pérez-Alenza D, Silvan G, Peña L, Lopes CS, Illera JC: Serum and intratumoural GH and IGF-I concentrations: prognostic factors in the outcome of canine mammary cancer. Res Vet Sci; 2010 Dec;89(3):396-403
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biological implication of the growth hormone/insulin like growth factor-I (GH/IGF-I) axis in canine mammary tumours (CMT) has been recently demonstrated, however its clinical and prognostic implications are unknown.
  • Hormonal determinations were done by enzyme immunoassays techniques validated for canine species in serum and tumour tissue from 32 bitches with CMT and in serum and normal mammary tissue from 10 controls.
  • Serum and tissular GH and IGF-I concentrations were significantly higher in the case of malignant tumour compared with benign and controls.
  • GH and IGF-I elevated concentrations were significantly associated with tumour relapse and/or metastases during follow-up and in dogs with reduced survival times; however these parameters were not independent prognostic factors in multivariate analysis.
  • [MeSH-major] Breast Neoplasms / veterinary. Dog Diseases / diagnosis. Growth Hormone / blood. Insulin-Like Growth Factor I / analysis
  • [MeSH-minor] Animals. Breast / chemistry. Breast / pathology. Dogs. Estrogen Receptor alpha / analysis. Female. Immunoenzyme Techniques / veterinary. Neoplasm Metastasis. Prognosis. Prospective Studies. Receptors, Progesterone / analysis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20381105.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


50. Malhaire C, El Khoury C, Thibault F, Athanasiou A, Petrow P, Ollivier L, Tardivon A: Vacuum-assisted biopsies under MR guidance: results of 72 procedures. Eur Radiol; 2010 Jul;20(7):1554-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical accuracy of magnetic resonance imaging-guided breast vacuum-assisted biopsy (MR-VAB).
  • RESULTS: Twenty-three patients (median age 51 years) were at high risk (BRCA1 = 11, BRCA2 = 7, familial risk = 5), 23 had a suspected local recurrence of breast cancer.
  • According to histopathology results, 29 lesions were benign, 10 were high-risk (papillary = 2, radial scar = 1, atypical epithelial hyperplasia = 7) and 33 malignant (ductal carcinoma in situ = 8, invasive cancers = 25).
  • CONCLUSION: MRI-guided VAB represents an accurate tool for the histological diagnosis of lesions visible only at MRI.
  • [MeSH-major] Biopsy. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bleomycin. Breast / surgery. Dactinomycin. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Tumor Burden. Vacuum. Vinblastine

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20119729.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 1CC1JFE158 / Dactinomycin; 5V9KLZ54CY / Vinblastine; VAB protocol
  •  go-up   go-down


51. Kukreti S, Cerussi AE, Tanamai W, Hsiang D, Tromberg BJ, Gratton E: Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy. Radiology; 2010 Jan;254(1):277-84
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy.
  • PURPOSE: To develop a near-infrared spectroscopic method to identify breast cancer biomarkers and to retrospectively determine if benign and malignant breast lesions could be distinguished by using this method.
  • By using self-referencing differential spectroscopy (SRDS) analysis, the existence of specific spectroscopic signatures of breast lesions on images acquired by using diffuse optical spectroscopy imaging in the wavelength range (650-1000 nm) was established.
  • There were 17 patients with benign breast tumors and 22 patients with malignant breast tumors.
  • RESULTS: Discrimination analysis helped separate malignant from benign tumors.
  • A total of 40 lesions (22 malignant and 18 benign) were analyzed.
  • CONCLUSION: The SRDS method revealed localized tumor biomarkers specific to pathologic state.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2000 Sep;72(3):383-91 [10989610.001]
  • [Cites] Breast Cancer Res Treat. 2007 Sep;104(3):249-55 [17051424.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1016-22 [11308247.001]
  • [Cites] Magn Reson Med. 2001 Jun;45(6):994-1000 [11378876.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):45-54 [11678308.001]
  • [Cites] J Biomed Opt. 2002 Jan;7(1):60-71 [11818013.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1197-203 [12189222.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1134-43 [14648561.001]
  • [Cites] Breast. 2003 Jun;12(3):179-82 [14659324.001]
  • [Cites] J Biomed Opt. 2004 Jan-Feb;9(1):230-8 [14715078.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):464-73 [15189083.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):541-52 [15189092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6468-73 [9177241.001]
  • [Cites] Radiology. 1998 Oct;209(1):269-75 [9769842.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):159-64 [10441019.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3A):1737-46 [10470108.001]
  • [Cites] Radiology. 2004 Nov;233(2):424-31 [15516615.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2451-68 [15901948.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] J Lipid Res. 2005 Sep;46(9):1983-90 [15961785.001]
  • [Cites] Radiology. 2005 Oct;237(1):57-66 [16183924.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051503 [16292947.001]
  • [Cites] Br J Cancer. 2006 Feb 13;94(3):427-35 [16465174.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S302-5 [16507398.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):325-32 [16786567.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):044005 [16965162.001]
  • [Cites] Expert Rev Med Devices. 2007 Jan;4(1):83-95 [17187474.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):020509 [17477706.001]
  • [Cites] Radiology. 2001 Jan;218(1):261-6 [11152812.001]
  • (PMID = 20032159.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA142989; United States / NCI NIH HHS / CA / U54 CA136400-01; None / None / / P41 RR001192-31; United States / NCI NIH HHS / CA / R01 CA142989-01; United States / NCRR NIH HHS / RR / P41 RR001192-31; United States / NIBIB NIH HHS / EB / R01 EB000559; United States / NCI NIH HHS / CA / U54 CA136400-02; United States / NCI NIH HHS / CA / U54 CA105480-05; United States / NCI NIH HHS / CA / U54 CA105480; United States / NCI NIH HHS / CA / U54 CA136400; United States / NCI NIH HHS / CA / R01 CA142989-02; United States / NCI NIH HHS / CA / P30-CA62203; United States / NCRR NIH HHS / RR / P41 RR003155; United States / NCRR NIH HHS / RR / P41 RR001192; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCRR NIH HHS / RR / P41-RR01192
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2797652
  •  go-up   go-down


52. Galiè M, Farace P, Merigo F, Fiorini S, Tambalo S, Nicolato E, Sbarbati A, Marzola P: Washout of small molecular contrast agent in carcinoma-derived experimental tumors. Microvasc Res; 2009 Dec;78(3):370-8
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Washout of small molecular contrast agent in carcinoma-derived experimental tumors.
  • The use of contrast-enhanced magnetic resonance imaging (MRI) for the assessment of breast carcinomas reveals satisfactory sensitivity, but due to low specificity, it does not obviate the need for subsequent tissue sampling.
  • Its capability to differentiate benign from malignant lesion is under continuous investigation.
  • In particular, the study of the washout pattern is considered a promising tool to improve in vivo diagnosis and even to evaluate the response under chemotherapy.
  • To provide a comprehensive characterization of this parameter in malignant tumor models, in vivo mapping of the washout of small molecular contrast agent (Gd-DTPA, molecular weight 0.57 kDa) was carried out in three transplanted/spontaneous mammary tumors, which differed in their histopathological and microvascular features.
  • It resulted that in all models around 40% of tumor volume lacks efficient washout; washout areas are frequently, but not always, restricted to the tumor periphery and that non-washout areas are not restricted to necrotic regions.
  • Difference in the distribution of lymphatic vessels characterized spontaneous vs. transplanted tumors but did not produce a corresponding different washout pattern, confirming that Gd-DTPA drainage does not mainly depend on lymphatic architecture.
  • Finally, the efficiency of washout is correlated with parameters obtainable during the earlier phases of the enhancement curve and in malignant tumors it could be indirectly estimated from them.
  • [MeSH-major] Contrast Media / pharmacokinetics. Gadolinium DTPA / pharmacokinetics. Mammary Neoplasms, Experimental / diagnosis
  • [MeSH-minor] Animals. Female. Lymphatic Vessels / pathology. Mice. Mice, Inbred Strains. Microvessels / pathology. Neoplasm Transplantation. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804787.001).
  • [ISSN] 1095-9319
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


53. Chivukula M, Domfeh A, Carter G, Tseng G, Dabbs DJ: Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications. Appl Immunohistochem Mol Morphol; 2009 Dec;17(6):495-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of RC in these neoplasms may signify some degree of host response to tumor and seems to be a sign of poor prognosis for some neoplasms.
  • RC in breast cancer is vaguely defined in the older literature.
  • We have observed periodically similar RC in a subset of high-grade ductal carcinoma in situ (HGDCIS) in breast specimens.
  • It is also critically important to recognize HGDCIS-RC for diagnostic purposes, as the differential diagnosis of RC includes, benign associations such as papilloma, fibrocystic changes and periductal mastitis.
  • Further outcome studies are necessary to determine if it has a clinical impact akin to other tumors with RC.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407654.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 13
  •  go-up   go-down


54. Yang W, Zhang S, Chen Y, Li W, Chen Y: Shape symmetry analysis of breast tumors on ultrasound images. Comput Biol Med; 2009 Mar;39(3):231-8
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shape symmetry analysis of breast tumors on ultrasound images.
  • Shape characteristics of malignant and benign breast tumors are significantly different.
  • In this paper, the reflective symmetry of breast tumor shapes on ultrasound images was investigated.
  • A new reflective symmetry measure (RSML) derived from multiscale local area integral invariant was proposed to quantify the shape symmetry of breast tumor, which could be computed directly from the binary mask image without the shape parameterization in terms of arc length.
  • The performance of several symmetry measures for differentiating malignant and benign breast tumors at varying scales was evaluated and compared by receiver operating characteristic (ROC) analysis.
  • RSML with Gaussian kernel at scale 0.04 (related to the maximal diameter) achieved the highest area under the ROC curve (0.85) on the image data of 168 tumors (104 benign and 64 malignant).
  • The experimental results showed that the reflective symmetry of breast tumor shape was capable of providing potential diagnostic information, which could be characterized quantitatively by RSML with the appropriate scale parameter.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Ultrasonography / methods. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178908.001).
  • [ISSN] 1879-0534
  • [Journal-full-title] Computers in biology and medicine
  • [ISO-abbreviation] Comput. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Singh SS, Velusami SD: Syringomatous adenoma of the nipple: report of a case. Indian J Pathol Microbiol; 2007 Oct;50(4):808-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syringomatous adenoma of the nipple is a rarely encountered neoplasm of the breast with histological features similar to eccrine syringoma of the skin.
  • This tumour which is locally invasive with high potential for recurrence if incompletely excised is considered benign and a complete excision is sufficient.
  • We report a case of syringomatous adenoma of the nipple in a postmenopausal diabetic woman who was incidentally found to have a subareolar mass in her right breast.
  • A clinicopathological study and histological differential diagnosis of this unusual tumour is described.
  • [MeSH-major] Nipples / pathology. Syringoma / diagnosis. Syringoma / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306564.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


56. Fujita T, Hayashi K, Katanoda K, Matsumura Y, Lee JS, Takagi H, Suzuki S, Mizunuma H, Aso T: Prevalence of diseases and statistical power of the Japan Nurses' Health Study. Ind Health; 2007 Oct;45(5):687-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For all diseases except ovarian cancer, the prevalence of a past diagnosis increased markedly with age, and incidence rates could be predicted based on the degree of increase in prevalence between two adjacent 5-yr age groups.
  • The predicted incidence rate for uterine myoma, hypercholesterolemia, and hypertension was > or =3.0 (per 1,000 women, per year), while the rate of thyroid disease, hepatitis, gallstone disease, and benign breast tumor was predicted to be > or =1.0.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057812.001).
  • [ISSN] 0019-8366
  • [Journal-full-title] Industrial health
  • [ISO-abbreviation] Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


57. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC: Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol; 2005 Oct 1;23(28):6846-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis was obtained in 69 of these patients, including 37 (54%) with solitary metastases and 32 (46%) with lesions unrelated to the lung primary.
  • Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%).
  • The six malignancies consisted of carcinoma of the breast in two patients, and carcinoma of the orbit, esophagus, prostate, and non-Hodgkin's lymphoma in one patient each.
  • Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture.
  • CONCLUSION: Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Inflammation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192576.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


58. Ikeda S, Shibata T, Funakoshi N: Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast. Rinsho Byori; 2005 Jun;53(6):487-93
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast.
  • Telomerase activity is associated with immortality and is expressed in various malignant tumors.
  • In this study, the expression of TERT was investigated by immunocytochemistry to determine whether it is a useful marker for differential diagnosis in benign or malignant breast tumors.
  • We examined imprint smears prepared from 63 surgically resected breast lesions, and 27 cases of secretion or aspiration cytology smears had been routinely diagnosed.
  • In conclusion, the expression of TERT protein might be a useful marker for differential diagnosis in malignant and benign breast tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. DNA-Binding Proteins / analysis. Telomerase / analysis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. In Situ Hybridization. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rinsho Byori.2005 Aug;53(8):748
  • (PMID = 16026073.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


59. Preda A, Novikov V, Möglich M, Floyd E, Turetschek K, Shames DM, Roberts TP, Corot C, Carter WO, Brasch RC: Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation. Eur Radiol; 2005 Nov;15(11):2268-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.
  • Carboxymethyldextran (CMD)-A2-Gd-DOTA, a slow clearance blood pool contrast agent with a molecular weight of 52.1 kDa, designed to have intravascular residence for more than 1 h, was evaluated for its potential to characterize and differentiate the microvessels of malignant and benign breast tumors.
  • Precontrast single-slice inversion-recovery snapshot FLASH and dynamic contrast-enhanced MRI using an axial T1-weighted three-dimensional spoiled gradient recalled sequence was performed in 30 Sprague-Dawley rats with chemically induced breast tumors.
  • Endothelial transfer coefficient and fractional plasma volume of the breast tumors were estimated from MRI data acquired with CMD-A2-Gd-DOTA enhancement injected at a dose of 0.1 mmol Gd/kg body weight using a two-compartment bidirectional model of the tumor tissue.
  • The correlation between MRI microvessel characteristics and histopathological tumor grade was determined using the Scarff-Bloom-Richardson method.
  • Using CMD-A2-Gd-DOTA, no significant correlations were found between the MR-estimated endothelial transfer coefficient or plasma volumes with histological tumor grade.
  • Analysis of CMD-A2-Gd-DOTA-enhanced MR kinetic data failed to demonstrate feasibility for the differentiation of benign from malignant tumors or for image-based tumor grading.
  • [MeSH-major] Magnetic Resonance Imaging. Mammary Neoplasms, Experimental / blood supply. Mammary Neoplasms, Experimental / pathology. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012822.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA82923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / carboxymethyl-dextran-A2-gadolinium-DOTA
  •  go-up   go-down


60. Bettstetter M, Woenckhaus M, Wild PJ, Rümmele P, Blaszyk H, Hartmann A, Hofstädter F, Dietmaier W: Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol; 2005 Apr;205(5):606-14
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer.
  • Maspin, a member of the serpin family, has been reported to suppress metastasis and angiogenesis in breast and prostate cancers.
  • Overexpression of maspin was associated with adverse prognostic features in several other tumours.
  • Significant upregulation of maspin expression was found in MSI-H tumours compared to both MSS/MSI-L tumours and matched benign colonic mucosa.
  • Intense nuclear maspin immunostaining was seen specifically in MSI-H tumours (p = 0.013), de-differentiated tumours (p = 0.006), and at the invasion front.
  • These findings provide new insights into the role of maspin in colorectal cancer progression and may be useful for diagnosis and treatment strategies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Microsatellite Repeats. Neoplasm Proteins / metabolism. Serpins / metabolism
  • [MeSH-minor] Blotting, Western. Cell Nucleus / metabolism. CpG Islands. Cytoplasm / metabolism. DNA Methylation. DNA, Neoplasm / genetics. Genes, Tumor Suppressor. Humans. Neoplasm Invasiveness. Neoplasm Staging. Promoter Regions, Genetic. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription, Genetic

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714592.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


61. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


62. Benarroch-Gampel J, Riall TS: Extrapancreatic malignancies and intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg; 2010 Oct 27;2(10):363-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapancreatic malignancies and intraductal papillary mucinous neoplasms of the pancreas.
  • Over the last two decades multiple studies have demonstrated an increased incidence of additional malignancies in patients with intraductal papillary mucinous neoplasms (IPMNs).
  • The majority of these additional cancers occur before or concurrent with the diagnosis of IPMN.
  • The gastrointestinal tract is most commonly involved in secondary malignancies, with benign colon polyps and colon cancer commonly seen in western countries and gastric cancer commonly seen in Asian countries.
  • Other extrapancreatic malignancies associated with IPMNs include benign and malignant esophageal neoplasms, gastrointestinal stromal tumors, carcinoid tumors, hepatobiliary cancers, breast cancers, prostate cancers, and lung cancers.
  • Routine screening studies (breast and prostate) should be carried out as currently recommended for patient's age both before and after the diagnosis of IPMN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160845.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999205
  • [Keywords] NOTNLM ; Intraductal papillary mucinous neoplasm / Invasive / Malignant potential / Non-invasive / Secondary malignancy
  •  go-up   go-down


63. Corben AD, Nehhozina T, Garg K, Vallejo CE, Brogi E: Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma. Am J Surg Pathol; 2010 Aug;34(8):1211-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma.
  • The occurrence of benign epithelial inclusions in lymph nodes is well documented and can sometimes mimic metastatic carcinoma.
  • Benign müllerian inclusions, such as endometriosis and endosalpingiosis, are common in pelvic and para-aortic lymph nodes, but their presence in supradiaphragmatic lymph nodes is a rare event.
  • We report our experience with 3 patients found to have endosalpingiosis in axillary sentinel lymph nodes obtained for staging of breast carcinoma.
  • Endosalpingiosis had been misinterpreted as metastatic carcinoma at another hospital in 1 of the 3 patients, with subsequent dissection of 19 additional benign axillary lymph nodes.
  • Morphologic identification of ciliated cells and "peg" cells is most helpful to recognize this benign inclusion, and positive immunoreactivity for WT1 and/or PAX8 can be used to support the diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Diagnostic Errors / prevention & control. Epithelial Cells / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cilia. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Staging. Paired Box Transcription Factors / analysis. Predictive Value of Tests. Sentinel Lymph Node Biopsy. Unnecessary Procedures. WT1 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631604.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / WT1 Proteins
  • [Number-of-references] 32
  •  go-up   go-down


64. Noske A, Pahl S, Fallenberg E, Richter-Ehrenstein C, Buckendahl AC, Weichert W, Schneider A, Dietel M, Denkert C: Flat epithelial atypia is a common subtype of B3 breast lesions and is associated with noninvasive cancer but not with invasive cancer in final excision histology. Hum Pathol; 2010 Apr;41(4):522-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flat epithelial atypia is a common subtype of B3 breast lesions and is associated with noninvasive cancer but not with invasive cancer in final excision histology.
  • The biological behavior and the optimal management of benign breast lesions with uncertain malignant potential, the so-called B3 lesions, found in breast needle core biopsies is still under debate.
  • Biopsies were image-guided (31 by ultrasound, 85 stereotactic vacuum-assisted, 6 unknown) for evaluation of breast abnormalities.
  • Final excision histology was benign in 73 (90.2%) and malignant in 8 (9.8%) patients (2 invasive cancer, 6 ductal carcinoma in situ).
  • In our study, flat epithelial atypia and atypical ductal hyperplasia are common lesions of the B3 category in needle core biopsies of the breast.
  • We conclude that an excision biopsy after diagnosis of flat epithelial atypia is recommended depending on clinical and radiologic findings.
  • [MeSH-major] Breast Neoplasms / pathology. Mammary Glands, Human / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Middle Aged. Neoplasm Invasiveness. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc.
  • (PMID = 20004938.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Engohan-Aloghe C, Hottat N, Cosaert J, Boutemy R, Fayt I, Noël JC: Evaluation of accuracy of fine needle aspiration cytology in BI-RADS3 category breast lesions: cytohistological correlation in 337 cases. Cytopathology; 2010 Jun;21(3):161-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of accuracy of fine needle aspiration cytology in BI-RADS3 category breast lesions: cytohistological correlation in 337 cases.
  • OBJECTIVE: To evaluate the accuracy of fine needle aspiration cytology (FNAC) in BI-RADS3 breast lesions.
  • RESULTS: The histological diagnosis showed that 88% (59/67) of BI-RADS3 breast lesions were benign.
  • However, the correlation between cytology and histology showed that most of these lesions were benign and that finally FNAC remains a useful and accurate test in the management of these lesions.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Breast / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744191.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Schiffhauer LM, Boger JN, Bonfiglio TA, Zavislan JM, Zuley M, Fox CA: Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections. BMC Cancer; 2009;9:265
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections.
  • BACKGROUND: Needle core biopsy, often in conjunction with ultrasonic or stereotactic guided techniques, is frequently used to diagnose breast carcinoma in women.
  • This paper reports the progress in developing techniques to rapidly screen needle core breast biopsy and surgical specimens at the point of care.
  • CSLM requires minimal tissue processing and has the potential to reduce the time from excision to diagnosis.
  • METHODS: Needle core breast specimens from 49 patients were imaged at the time of biopsy.
  • These lesions had been characterized under the Breast Imaging Reporting And Data System (BI-RADS) as category 3, 4 or 5.
  • Immediately following imaging, the specimens were fixed in buffered formalin and submitted for histological processing and pathological diagnosis.
  • RESULTS: The pathologic diagnoses by standard histology were 7 invasive ductal carcinomas, 2 invasive lobular carcinomas, 3 ductal carcinomas in-situ (CIS), 21 fibrocystic changes/proliferative conditions, 9 fibroadenomas, and 5 other/benign; two were excluded due to imaging difficulties.
  • Morphologic and cellular features of benign and cancerous lesions were identified in the confocal images and were comparable to standard histologic sections of the same tissue.
  • Morphologic and cellular features of benign and cancerous lesions were identified in the confocal images.
  • Additional studies are needed to 1.) establish correlation of the confocal and traditional histologic images for the various diseases of the breast; 2.) validate diagnostic use of CSLM and; 3.) further define features of borderline lesions such as well-differentiated ductal CIS vs. atypical hyperplasia.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Microscopy, Confocal / methods
  • [MeSH-minor] Biopsy. Cell Proliferation. Contrast Media / pharmacology. Female. Humans. Medical Oncology / methods. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Oct;33(10):975-82 [12395369.001]
  • [Cites] Pancreatology. 2001;1(1):48-57 [12120268.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • [Cites] Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1 [11114647.001]
  • [Cites] BMC Cancer. 2008;8:21 [18215290.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051602 [16292950.001]
  • [Cites] J Invest Dermatol. 1999 Sep;113(3):293-303 [10469324.001]
  • [Cites] Clin Dermatol. 2003 Sep-Oct;21(5):359-69 [14678715.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):839-46 [12859385.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051901 [17994884.001]
  • (PMID = 19650910.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC3087331
  •  go-up   go-down


67. Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirström K, Llombart-Bosch A, Timmermans-Wielenga V, Rank F, Gromova I: 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol Cell Proteomics; 2008 Oct;7(10):1795-809
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.
  • Established histopathological criteria divide invasive breast carcinomas into defined groups.
  • The remaining 10% include rarer types such as tubular, cribriform, mucinous, papillary, medullary, metaplastic, and apocrine breast carcinomas.
  • Molecular profiling technologies, on the other hand, subdivide breast tumors into five subtypes, basal-like, luminal A, luminal B, normal breast tissue-like, and ERBB2-positive, that have different prognostic characteristics.
  • IACs make up 0.5-3% of the invasive ductal carcinomas, and despite the fact that they are morphologically distinct from other breast lesions, there are presently no standard molecular criteria available for their diagnosis and as a result no precise information as to their prognosis.
  • By comparing the protein expression profiles of apocrine macrocysts and non-malignant breast epithelial tissue we have previously reported the identification of a few proteins that are specifically expressed by benign apocrine lesions as well as by the few IACs that were available to us at the time.
  • Here we reiterate our strategy to reveal apocrine cell markers and present novel data, based on the analysis of a considerably larger number of samples, establishing that IACs correspond to a distinct molecular subtype of breast carcinomas characterized by the expression of 15-prostaglandin dehydrogenase alone or in combination with a novel form of acyl-CoA synthetase medium-chain family member 1 (ACSM1).
  • Moreover we show that 15-prostaglandin dehydrogenase is not expressed by other breast cancer types as determined by gel-based proteomics and immunohistochemistry analysis and that antibodies against this protein can identify IACs in an unbiased manner in a large breast cancer tissue microarray making them potentially useful as a diagnostic aid.
  • [MeSH-major] Apocrine Glands / enzymology. Apocrine Glands / pathology. Breast Neoplasms / classification. Breast Neoplasms / enzymology. Coenzyme A Ligases / metabolism. Hydroxyprostaglandin Dehydrogenases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cohort Studies. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunohistochemistry. Immunophenotyping. Middle Aged. Neoplasm Invasiveness. Paraffin Embedding. Phenotype. Silver Staining. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632593.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases; EC 1.1.1.141 / 15-hydroxyprostaglandin dehydrogenase; EC 6.2.1.- / ACSM1 protein, human; EC 6.2.1.- / Coenzyme A Ligases
  •  go-up   go-down


68. Seefeld M, El Tarhouny S, Fan AX, Hahn S, Holzgreve W, Zhong XY: Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors. Int J Biol Markers; 2008 Apr-Jun;23(2):69-73
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors.
  • OBJECTIVES: In order to assess the potential biomolecules for breast cancer, we analyzed in parallel the levels of cell-free glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and cell-free nucleosomes in serum samples from patients with benign and malignant breast tumors.
  • METHODS: Twenty-three patients with benign breast tumors, 27 patients with breast cancer, and 32 age-matched healthy women were recruited.
  • RESULTS: The levels of cell-free GAPDH were significantly higher in the serum samples of patients with benign and malignant breast tumors than in those of the control group (median 37,966 GE/mL, range 3,802-130,104 versus 11,770 GE/mL, range 2,198-73,522, p=0.035 and median 40,698 GE/mL, range 3,644-192,482 versus 11,770 GE/mL range 2,198-73,522, p=0.001).
  • There was, however, no significant difference between healthy individuals and women with benign breast tumors or breast cancer in terms of nucleosomes determined by ELISA.
  • CONCLUSION: Our data suggest that the cell-free serum GAPDH DNA assayed by quantitative PCR is a better biomarker than nucleosomes assayed by ELISA in patients with breast tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. DNA / blood. Enzyme-Linked Immunosorbent Assay / methods. Nucleosomes. Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18629778.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nucleosomes; 9007-49-2 / DNA; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


69. Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, Tangerud A, Tobin D: Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med; 2006 Sep;47(9):1434-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.
  • The present study was a proof-of-concept study to provide an initial indication of the efficacy and safety of imaging malignant breast tumors using (99m)Tc-NC100692.
  • METHODS: Sixteen patients with suggestive mammographic findings and 4 patients with benign lesions were included.
  • The "standard of truth" was based on the histopathologic diagnosis of the recruited patients.
  • Overall, the efficacy data in subjects with suspected breast lesions suggest that (99m)Tc-NC100692 scintigraphy may be effective in detecting malignant lesions.
  • The use of (99m)Tc-NC100692 in subjects with breast cancer is safe and well tolerated.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / radionuclide imaging. Integrin alphaVbeta3 / metabolism. Neoplasm Proteins / metabolism. Organotechnetium Compounds / pharmacokinetics. Peptides, Cyclic / pharmacokinetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Nucl Med. 2007 Apr;48(4):567
  • (PMID = 16954550.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin alphaVbeta3; 0 / Neoplasm Proteins; 0 / Organotechnetium Compounds; 0 / Peptides, Cyclic; 0 / Radiopharmaceuticals; 0 / technetium 99m NC 100692
  •  go-up   go-down


70. Buch A, Rout P, Makhija P: Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump. Indian J Pathol Microbiol; 2006 Apr;49(2):259-61
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump.
  • An unusual combination of two benign breast neoplasms adenomyoepithelioma and phyllodes tumor presenting as a solitary breast lump have been described.
  • Both these tumors have tendencies to recur and have malignant potential.
  • This patient also presented with a recurrent breast neoplasm.
  • [MeSH-major] Adenomyoma / pathology. Breast Neoplasms / pathology. Myoepithelioma / pathology. Neoplasms, Multiple Primary / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2006 Jul;49(3):476
  • (PMID = 16933731.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


71. Izzo L, Stasolla A, Basso L, Caputo M, Kharrub Z, Marini M, Mingazzini P, Fiori E, Galati G, D'Aprile MR, Mele LL, Marini M: Characterization of tumoral lesions of the breast: preliminary experience with multislice spiral CT. J Exp Clin Cancer Res; 2005 Jun;24(2):209-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of tumoral lesions of the breast: preliminary experience with multislice spiral CT.
  • The aim of the present study was to validate low dose Multislice Spiral Computed Tomography (MSCT) in the diagnosis of breast lesions.
  • Fourteen patients with mammographic and ultrasound findings suspect of malignant neoplasm underwent dynamic MSCT of the breast under basal conditions and 1, 3, and 6 minutes after intravenous injection of iodinated contrast medium.
  • A correct diagnosis was achieved by MSCT in 7/8 malignant lesions, and in 6/6 benign lesions.
  • Sensitivity and specificity of MSCT in the diagnosis of malignancy of a lesion were 88% and 100%, respectively.
  • Our results suggest that MSCT is an effective diagnostic method to define suspicious breast lesions, and a valid alternative to Magnetic Resonance Imaging, especially when the latter is not feasible.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Mammography / methods. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110753.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Iodine Radioisotopes
  •  go-up   go-down


72. Fulciniti F, Mansueto G, Vetrani A, Accurso A, Fortunato A, Palombini L: Metaplastic breast carcinoma on fine-needle cytology samples: a report of three cases. Diagn Cytopathol; 2005 Sep;33(3):205-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic breast carcinoma on fine-needle cytology samples: a report of three cases.
  • Metaplastic breast carcinoma (MBC) may have a varied presentation on fine-needle cytology samples.
  • Because of the various presentation of MBC on fine-needle cytology samples and the possible influence of needle "sampling" on the cytological specimen, the spectrum of differential diagnoses to be considered may encompass a number of benign and malignant entities, like keratinous subareolar cysts, malignant fibroepithelial lesions with myxo-chondroid stroma, and true sarcomas of the breast, with cartilaginous metaplasia.
  • It is the Authors' feeling that, with optimal samples, the cytomorphological findings of this rare variant of breast carcinoma permit its accurate pre-operative diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Metastasis / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Sarcoma / metabolism. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16078244.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Schulz-Wendtland R, Bock K, Aichinger U, de Waal J, Bader W, Albert US, Duda VF: [Ultrasound examination of the breast with 7.5 MHz and 13 MHz-transducers: scope for improving diagnostic accuracy in complementary breast diagnostics?]. Ultraschall Med; 2005 Jun;26(3):209-15
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultrasound examination of the breast with 7.5 MHz and 13 MHz-transducers: scope for improving diagnostic accuracy in complementary breast diagnostics?].
  • [Transliterated title] Mamma-Sonographie mit 7.5 MHz versus 13 MHz: Ist eine Verbesserung der diagnostischen Sicherheit im Rahmen der komplementären Mammadiagnostik möglich?
  • AIM: Complementary diagnostic methods in early diagnosis of breast cancer are used to increase diagnostic accuracy and minimize unnecessary invasive diagnostic procedures.
  • Aim of the following prospective, open multicenter clinical study was to define the value of high-frequency breast ultrasound with 13 MHZ transducers compared to standard breast ultrasound with 7.5 MHz.
  • METHOD: Data of 810 female patients, aged 45 to 60 years, with 819 suspicious breast lesions evaluated by four participating centres between October 1996 and December 1997.
  • Standardised breast ultrasound was performed uniformly using a AU4 IDEA diagnostic ultrasound system by Esaote-Biomedica in addition to a standardised procedure of clinical examination and standard-2view-mammography.
  • RESULTS: The histopathological evaluation showed 435 benign and 384 malignant findings.
  • Regarding tumour size, mammography gave the highest sensitivity in detection of pre-invasive cancers (DCIS).
  • High-frequency breast ultrasound (13 MHz) proved to have a higher diagnostic accuracy compared to standard breast ultrasound (7,5 MHz) regardless of tumour size.
  • Sensitivity was especially improved in case of small invasive tumours (pT1a) with 78 % versus 56 %, respectively.
  • CONCLUSIONS: We conclude that high-frequency ultrasound is a valueable additive tool especially in the diagnosis of small tumours, improving diagnostic safety and reducing unnecessary invasive diagnostic procedures.
  • [MeSH-major] Breast Diseases / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948057.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Kamate B, Traore CB, Diallo D, Foko I, Sangare F, Malle B, Coulibaly B, Mounkoro N, Bayo S: [Epidemiology and morphology of breast benign tumors in Mali: about 186 cases]. Mali Med; 2008;23(3):36-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology and morphology of breast benign tumors in Mali: about 186 cases].
  • [Transliterated title] Epidemiologie et morphologie des tumeurs benignes du sein au Mali: a propos de 186 cas.
  • BACKGROUND: Mammary tumors are frequent.
  • Benign tumors are more frequent, and are characterized by a possibility of recurrence or malignant transformation.
  • The aim of this study was to describe the epidemiological and morphological characteristics of breast benign tumors.
  • The study had concerned all benign tumors confirmed by histology.
  • FINDINGS: In total, 186 benign tumors were diagnosed over 611 mammary pathologies (30.44%).
  • The main complaint was feeling a nodule in the breast (91.9%).
  • The most affected breast was the right side (50.8%).
  • Tumor sizes were variable, and the color changed through white to yellow.
  • Histological aspects were: fibroadenoma (72%), lipoma (8.6%), tubular adenoma (5.9%), papilloma (5.4%), lactating adenoma (3.8%), phyllodes tumor (3.8%), and syringomatous tumor (0.5%).
  • CONCLUSION: Benign tumors are frequent in mammary pathology.
  • The patients need a follow-up because of the recurrence or the malignant transformation of these tumors.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617151.001).
  • [ISSN] 1993-0836
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mali
  •  go-up   go-down


75. Kondi-Pafitis A, Kairi-Vassilatou E, Grapsa D, Kalkounou I, Vassilikostas G, Psichogios I: A large benign vascular neoplasm of the male breast. A case report and review of the literature. Eur J Gynaecol Oncol; 2005;26(4):454-6
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A large benign vascular neoplasm of the male breast. A case report and review of the literature.
  • Breast hemangiomas are extremely rare neoplasms in the male population.
  • We report a case of a 77-year old man with a breast hemangioma which was detected in physical examination as a small nodule ten years after a chest injury.
  • The final histological diagnosis was hemangioma of the breast, 6 cm in the largest diameter.
  • To our knowledge, this is the largest benign vascular breast neoplasm in a male patient reported up to date.
  • The rarity of the lesion and its differential diagnosis from angiosarcoma are discussed while the problems encountered in the correct diagnosis and classification of this tumor are also presented.
  • The need for extreme caution in the interpretation of the histological characteristics of all palpable vascular tumors of the breast is emphasized.
  • [MeSH-major] Breast Neoplasms, Male / diagnosis. Hemangioma / diagnosis

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Gynaecol Oncol. 2005;26(6):667; author reply 667-8 [16398236.001]
  • (PMID = 16122203.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 10
  •  go-up   go-down


76. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY: Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer; 2009;8:105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.
  • METHODS: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls.
  • RESULTS: While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022).
  • The level of ccf nDNA was also associated with tumor-size (<2 cm vs. >2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034).
  • Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001).
  • CONCLUSION: Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Cell Nucleus / genetics. DNA, Mitochondrial / blood
  • [MeSH-minor] Case-Control Studies. Cell-Free System. Cohort Studies. Diagnosis, Differential. Female. Health. Humans. Lymph Nodes / pathology. Neoplasm Metastasis. ROC Curve. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):905-8 [16900126.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] BMC Cancer. 2006;6:269 [17116247.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):157-63 [17280876.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):53-7 [17320491.001]
  • [Cites] Acta Paediatr. 2007 May;96(5):644-7 [17376185.001]
  • [Cites] Int J Biol Markers. 2007 Apr-Jun;22(2):95-9 [17549664.001]
  • [Cites] Arch Gynecol Obstet. 2007 Oct;276(4):327-31 [17431649.001]
  • [Cites] Prostate. 2008 Mar 1;68(4):408-17 [18196528.001]
  • [Cites] Clin Chem Lab Med. 2008;46(3):311-7 [18254709.001]
  • [Cites] JAMA. 2008 May 14;299(18):2151-63 [18477782.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):921-5 [18507037.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Jun;16(3):699-703 [18549658.001]
  • [Cites] Int J Biol Markers. 2008 Apr-Jun;23(2):69-73 [18629778.001]
  • [Cites] DNA Cell Biol. 2008 Aug;27(8):415-21 [18694299.001]
  • [Cites] Nat Med. 2008 Sep;14(9):985-90 [18670422.001]
  • [Cites] Obstet Gynecol. 2008 Oct;112(4):843-50 [18827127.001]
  • [Cites] Ann N Y Acad Sci. 2008 Aug;1137:175-9 [18837944.001]
  • [Cites] Cytokine. 2008 Oct;44(1):65-9 [18691902.001]
  • [Cites] Expert Rev Neurother. 2008 Dec;8(12):1841-52 [19086880.001]
  • [Cites] Neuroimage. 2009 Jun;46(2):394-410 [19236926.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1903-6 [11106320.001]
  • [Cites] Lancet. 2001 Jan 27;357(9252):310-1 [11214156.001]
  • [Cites] Swiss Med Wkly. 2001 Feb 10;131(5-6):70-4 [11383228.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:138-40 [11708467.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Feb;48(2):187-92 [7540567.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):592-9 [8600309.001]
  • [Cites] Brain Res Mol Brain Res. 1997 Dec 15;52(2):284-9 [9495550.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):920-4 [15856456.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1564-9 [16533782.001]
  • [Cites] Prenat Diagn. 2006 Apr;26(4):362-8 [16566058.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1087-91 [17047655.001]
  • (PMID = 19922604.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2780981
  •  go-up   go-down


77. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG: Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg; 2010 Jan;251(1):64-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management.
  • OBJECTIVE: To estimate the frequency of extrapancreatic neoplasms in patients with IPMN compared with those with ductal pancreatic cancer and a general referral population.
  • SUMMARY BACKGROUND DATA: Several studies have reported an increased risk of extrapancreatic neoplasms in patients with IPMN, but these studies focused only on those patients who underwent resection and excluded those patients treated nonoperatively.
  • Two control groups consisting of Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general referral population (3:1) were matched for gender and age at diagnosis, year of registration, and residence.
  • Logistic regression was used to assess the risk of a diagnosis of extrapancreatic neoplasms among cases versus controls.
  • The proportion of IPMN patients having any extrapancreatic neoplasm diagnosed before or coincident to the index date was 52% (95% CI, 47%-56%), compared with 36% (95% CI, 32%-41%) in Group 1 (P < 0.001), and 43% (95% CI, 41%-46%) in Group 2 (P = 0.002).
  • Benign neoplasms most frequent in the IPMN group were colonic polyps (n = 114) and Barrett's neoplasia (n = 18).
  • The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n = 24), colorectal cancers (n = 19), and carcinoid neoplasms (n = 6).
  • CONCLUSIONS: Patients with IPMN have increased risk of harboring extrapancreatic neoplasms.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / therapy. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858708.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


78. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S: Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol; 2009 Apr;10(4):381-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
  • BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.
  • We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.
  • METHODS: 165 breast samples were obtained by fine-needle aspiration.
  • A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.
  • A two-way ANOVA model identified probe sets with differential expression in malignant and benign lesions while adjusting for scan dates.
  • FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.
  • A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).
  • In the validation set (n=71), the molecular predictor accurately classified 68 of 71 tumours (96%, 88-99%).
  • When the 165 samples were taken into account, 37 858 exon probe sets (5.4%) and 3733 genes (7.0%) were differently expressed in malignant and benign lesions (threshold: adjusted p<0.05).
  • In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.
  • INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.
  • Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.
  • [MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]
  • (PMID = 19249242.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


79. Ruiz-Delgado ML, López-Ruiz JA, Eizaguirre B, Saiz A, Astigarraga E, Fernández-Temprano Z: Benign adenomyoepithelioma of the breast: imaging findings mimicking malignancy and histopathological features. Acta Radiol; 2007 Feb;48(1):27-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign adenomyoepithelioma of the breast: imaging findings mimicking malignancy and histopathological features.
  • Adenomyoepithelioma of the breast is a rare neoplasm.
  • We present a case of a benign adenomyoepithelioma of the breast in an asymptomatic 60-year-old woman.
  • [MeSH-major] Adenomyoma / diagnosis. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Mammography / methods. Myoepithelioma / diagnosis. Ultrasonography, Mammary / methods
  • [MeSH-minor] Biopsy / methods. Breast / pathology. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Image Enhancement / methods. Middle Aged. Rare Diseases

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325921.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


80. Kallel R, Bahri Zouari I, Gouiaa N, Charfi S, Daoud E, Ayadi L, Makni S, Daoud J, Sellami Boudawara T: [Adenoid cystic carcinoma of the breast]. Cancer Radiother; 2009 Jul;13(4):323-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the breast].
  • [Transliterated title] Carcinome adénoïde kystique du sein.
  • Adenoid cystic carcinoma of the breast is a rare neoplasm, accounting for only 0.1% of all malignant breast tumours.
  • The clinical criteria is not specific and the radiographic examination showed a benign-appearing tumour.
  • The preoperative diagnosis is possible with fine-needle aspiration cytology.
  • The diagnosis is made by histological examination, presented a difficult differential diagnosis with cribriform carcinoma; so it is necessary to use histochemical or immunohistochemical techniques.
  • Compared to other locations, adenoid cystic carcinoma of the breast has a favorable prognosis.
  • The aim of our study is to describe the epidemiological, clinicopathological characteristics, the treatment and the prognosis of this rare type of breast tumour.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Adenoid Cystic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Combined Modality Therapy / methods. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464219.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 30
  •  go-up   go-down


81. Dillon MF, Hill AD, Quinn CM, O'Doherty A, McDermott EW, O'Higgins N: The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases. Ann Surg; 2005 Nov;242(5):701-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases.
  • OBJECTIVE: Preoperative core biopsy in breast cancer is becoming the standard of care.
  • METHODS: All patients undergoing core biopsy for breast abnormalities over a 5-year period (1999-2003) were reviewed.
  • The accuracy rates for each method of core biopsy, the histologic agreement between the core pathology and subsequent excision pathology, and the length of follow-up for cases of benign disease were studied.
  • Patients whose biopsies were benign but who were subsequently diagnosed with cancer underwent detailed review.
  • RESULTS: There were 2427 core biopsies performed over the 5-year period, resulting in a final diagnosis of cancer in 1384 patients, benign disease in 954 patients, and atypical disease in 89 patients.
  • False-negative biopsies occurred in 85 patients, and in 8 of these patients the diagnosis was delayed by greater than 2 months.
  • CONCLUSION: Ultrasound guidance should be used to perform core biopsies in evaluating all breast abnormalities visible on ultrasound.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Breast Diseases / pathology. Breast Diseases / ultrasonography. Cohort Studies. Diagnosis, Differential. False Negative Reactions. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidence. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Dec 15;89(12):2538-46 [11135213.001]
  • [Cites] Radiology. 1999 Mar;210(3):799-805 [10207484.001]
  • [Cites] Cancer. 2001 Apr 25;93(2):146-50 [11309781.001]
  • [Cites] Ann Surg. 2001 Jun;233(6):769-77 [11371735.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):244-9 [11393185.001]
  • [Cites] J Vasc Interv Radiol. 2001 Nov;12(11):1313-7 [11698631.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):853-9 [12115488.001]
  • [Cites] Am J Surg. 2002 Oct;184(4):353-5 [12383901.001]
  • [Cites] J Ultrasound Med. 2002 Nov;21(11):1221-6 [12418763.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):52-6 [12504658.001]
  • [Cites] Radiology. 2003 Mar;226(3):779-82 [12601206.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1824-31 [12673707.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):387-91 [12846688.001]
  • [Cites] Surgery. 2003 Oct;134(4):523-6; discussion 526-8 [14605609.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):491-3 [14616944.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):357-64 [14681944.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):245-51 [14716757.001]
  • [Cites] Acad Radiol. 2004 Mar;11(3):293-308 [15035520.001]
  • [Cites] Cancer. 1986 Jan 15;57(2):320-3 [3942963.001]
  • [Cites] Surg Gynecol Obstet. 1990 May;170(5):407-10 [2183373.001]
  • [Cites] Eur J Surg Oncol. 1991 Jun;17(3):237-9 [2044776.001]
  • [Cites] Br J Surg. 1992 Oct;79(10):1042-5 [1422715.001]
  • [Cites] Radiology. 1993 May;187(2):507-11 [8475299.001]
  • [Cites] Radiology. 1994 Sep;192(3):793-5 [8058949.001]
  • [Cites] Radiology. 1994 Nov;193(2):325-6; discussion 326-8 [7972737.001]
  • [Cites] Radiology. 1994 Nov;193(2):359-64 [7972743.001]
  • [Cites] AJR Am J Roentgenol. 1996 Feb;166(2):341-6 [8553943.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):773-7 [8756371.001]
  • [Cites] Clin Radiol. 1996 Aug;51(8):562-5 [8761393.001]
  • [Cites] Cancer Detect Prev. 1996;20(6):620-4 [8939348.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2340-5 [8941004.001]
  • [Cites] Radiology. 1997 Apr;203(1):151-7 [9122384.001]
  • [Cites] AJR Am J Roentgenol. 1997 Sep;169(3):697-701 [9275881.001]
  • [Cites] J Am Coll Surg. 2000 Mar;190(3):299-303 [10703854.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1017-21 [10737383.001]
  • [Cites] Radiology. 2000 Jul;216(1):255-9 [10887257.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):542-8 [10998652.001]
  • [Cites] Clin Radiol. 1997 Oct;52(10):764-7 [9366536.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):932-9 [9637557.001]
  • [Cites] Radiology. 1998 Sep;208(3):717-23 [9722851.001]
  • [Cites] J Ultrasound Med. 2001 Jan;20(1):43-9 [11149527.001]
  • (PMID = 16244544.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1409862
  •  go-up   go-down


82. Fabre Demard N, Boulet P, Prat X, Charra L, Lesnik A, Taourel P: [Breast MRI in invasive lobular carcinoma: diagnosis and staging]. J Radiol; 2005 Sep;86(9 Pt 1):1027-34
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast MRI in invasive lobular carcinoma: diagnosis and staging].
  • [Transliterated title] Apport de l'IRM dans le diagnostic et le bilan d'extension des cancers lobulaires infiltrants.
  • PURPOSE: To assess the use of breast MRI for the diagnosis and staging of invasive lobular carcinoma and its impact on surgical management.
  • For 3 patients MRI lead to biopsy of benign lesions but improved the surgical management in the 8 cases of new cancers: wider excision for 3 cases, planned breast conservation converted to mastectomy in 3 cases and excision of contralateral lesion in 2 cases.
  • CONCLUSION: Breast MRI is useful in diagnosis, staging and surgical management of invasive lobular breast carcinoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Lobular / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Humans. Image Enhancement. Mammography. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoplasm Staging. Patient Care Planning. Retrospective Studies. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224343.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


83. Soares Leite D, Lima de Lima PD, Ferreira Leal M, Suchi Chen E, Casartelli C, de Arruda Cardoso Smith M, Rodríguez Burbano R: Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation. Clin Exp Med; 2006 Dec;6(4):166-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation.
  • Fibroadenoma (FA) is a benign breast tumour that occurs in about 25% of women.
  • Cytogenetic studies suggest that numerical chromosomal aberrations may contribute to tumorigenesis, but chromosomal instability is still poorly characterised in breast cancer.
  • The aim of this study was to investigate numerical alterations of chromosome 21 in 15 breast FAs.
  • Classical cytogenetics analysis showed that all cells were diploidies with modal number varying between 43 and 47 chromosomes, and clonal chromosome alterations in 46.7% of tumours.
  • The study of benign proliferations and comparison with chromosome alterations in their malignant counterparts should result in an understanding of the genes acting in cell proliferation alone and those that cause these cells to both undergo malignant transformation and become invasive.
  • [MeSH-major] Aneuploidy. Breast Neoplasms / genetics. Chromosomes, Human, Pair 21 / genetics. Fibroadenoma / genetics. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191108.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


84. Chen YW, Chuang YW, Lai YC, Hsieh JS, Liu GC, Hou MF: Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor? Ann Nucl Med; 2006 Jan;20(1):45-50
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor?
  • OBJECTIVE: In this article, we will discuss the achievement of early dynamic lymphoscintigraphic protocol and compare detection of sentinel node between benign and malignant breast tumors, and whether pathologic factor is related or not.
  • The average age of patients was 47.6 +/- 9.8 years and all of them were clinically suspected of having breast cancer.
  • The average tumor was 2.1 +/- 1.1 cm in size.
  • All patients underwent surgery sixteen to twenty hours later and had a final pathological diagnosis.
  • From the summation image of dynamic study, identified axillary sentinel nodal activity was found as 80% in the group of benign breast tumor, but only 48% in the group of malignant breast tumor.
  • However, this short period of protocol is not always achievable to detect sentinel node, especially in the group with breast malignant lesions.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Breast Neoplasms / secondary. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Sentinel Lymph Node Biopsy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485574.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


85. Tse GM, Tan PH, Ma TK, Gilks CB, Poon CS, Law BK: CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast. J Clin Pathol; 2005 Nov;58(11):1185-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.
  • BACKGROUND/AIMS: CD44s, the standard form of CD44, has been shown to be downregulated during malignant transformation of breast cancers.
  • It has also been reported recently to be a useful marker in differentiating between benign and malignant papillary lesions of the breast, with high expression in the former.
  • CD44s expression in benign and malignant papillary lesions was evaluated.
  • METHODS: CD44s expression was assessed by immunohistochemistry in 101 benign papillomas and 59 papillary carcinomas (seven invasive papillary carcinomas, 41 papillary ductal carcinomas in situ, and 11 ductal carcinomas involving papillomas).
  • RESULTS: Patients' age and tumour size were significantly different between the papilloma and papillary carcinoma groups (p < 0.0001).
  • Using CD44s positive staining to differentiate between benign and malignant papillary lesions gives a sensitivity, specificity, and accuracy of 45%, 92%, and 62%, respectively.
  • CONCLUSIONS: CD44s may be useful as an adjunct in the evaluation of morphologically problematic cases of papillary lesion of the breast.
  • [MeSH-major] Antigens, CD44 / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Papilloma, Intraductal / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2004 Apr;19(2):465-71 [15024707.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1665-70 [15274338.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5702-11 [15313910.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):211-31 [15339042.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):23-31 [15385106.001]
  • [Cites] Hum Pathol. 1988 Mar;19(3):276-89 [2450059.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):939-47 [1698341.001]
  • [Cites] Cancer Cells. 1991 Sep;3(9):347-50 [1721518.001]
  • [Cites] J Cell Biol. 1992 Aug;118(4):971-7 [1380003.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):315-22 [1384226.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):323-30 [1384227.001]
  • [Cites] Curr Top Microbiol Immunol. 1993;184:47-63 [7508842.001]
  • [Cites] Bioessays. 1995 Jan;17(1):17-24 [7535522.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5424-33 [7585612.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(3):307-313 [8573713.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):862-4 [10690183.001]
  • [Cites] Histopathology. 2000 Sep;37(3):232-40 [10971699.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(3):125-35 [8781700.001]
  • [Cites] Clin Exp Metastasis. 1996 Oct;14(5):434-9 [8871537.001]
  • [Cites] Histopathology. 1998 Aug;33(2):107-16 [9762542.001]
  • [Cites] Virchows Arch. 1999 Jan;434(1):45-50 [10071234.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):625-32 [15832086.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(1):23-9 [11245336.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2539-46 [11745187.001]
  • [Cites] J Pathol. 2001 Nov;195(4):415-21 [11745672.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):34-9 [11893033.001]
  • [Cites] Histopathology. 2003 Jun;42(6):546-54 [12786890.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):548-54 [12712335.001]
  • [Cites] Pol J Pathol. 2003;54(4):243-7 [14998292.001]
  • [Cites] Genomics. 1995 Nov 1;30(1):115-7 [8595891.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):513-8 [8621236.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):259-61 [8654608.001]
  • (PMID = 16254109.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD44S antigen
  • [Other-IDs] NLM/ PMC1770758
  •  go-up   go-down


86. Flegg KM, Flaherty JJ, Bicknell AM, Jain S: Surgical outcomes of borderline breast lesions detected by needle biopsy in a breast screening program. World J Surg Oncol; 2010;8:78
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes of borderline breast lesions detected by needle biopsy in a breast screening program.
  • This study describes the outcome of surgical biopsies of the breast performed as a result of a borderline lesion being identified after screening mammography and subsequent workup.A secondary aim was to identify any parameters, such as a family history of breast cancer, or radiological findings that may indicate which borderline lesions are likely to be upgraded to malignancy after surgery.
  • METHODS: From a period of just over eight years, all patients of BreastScreen ACT&SENSW who were diagnosed with a borderline breast lesion were identified.
  • RESULTS: Of the 94 surgical biopsies performed due to the presence of a borderline breast lesion, 20% showed benign pathology, 55% remained as borderline lesions, 17% showed non-invasive malignancy and 7% showed invasive malignancy.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / surgery. Mass Screening / methods. Mastectomy / methods. Neoplasm Staging / methods
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. New South Wales. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2000 Jun;135(6):700-3 [10843367.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1253-7 [17438578.001]
  • [Cites] Pathology. 2002 Oct;34(5):410-6 [12408338.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):345-51 [12518358.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):234-9 [12673557.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Radiology. 2004 Jun;231(3):813-9 [15105449.001]
  • [Cites] Histopathology. 2004 Aug;45(2):148-54 [15279633.001]
  • [Cites] N Engl J Med. 1999 Feb 11;340(6):430-6 [9971867.001]
  • [Cites] Radiology. 1999 Mar;210(3):799-805 [10207484.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):534-43 [15767810.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):62-71 [15797294.001]
  • [Cites] Am J Surg. 2006 Oct;192(4):534-7 [16978969.001]
  • [Cites] AJR Am J Roentgenol. 2006 Oct;187(4):949-54 [16985141.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):35-41 [17095049.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):180-7 [17154175.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):704-11 [17151788.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):417-26 [17325484.001]
  • [Cites] Histopathology. 2007 Apr;50(5):607-14 [17394497.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1095-110 [12218567.001]
  • (PMID = 20822548.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2945347
  •  go-up   go-down


87. El-Attar NI, Gaefar HA: Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor. Egypt J Immunol; 2007;14(2):111-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
  • Breast cancer (BC) is the most frequent malignant tumor in women worldwide; its recurrence is a result of undetected metastasis present at the time of primary patient treatment.
  • The detection of cell-free RNA in plasma and serum of human subjects has found increasing applications in the field of medical diagnostics.This study aimed at evaluating plasma mammaglobin mRNA as a useful tumor marker for the diagnosis and the detection of metastasis in breast cancer at the time of diagnosis either alone or in combination with conventional serum tumor markers CA15.3 and/or CEA.
  • This study included 40 Egyptian females with primary breast cancer and 25 with different benign breast diseases.
  • There was a significance increase in plasma mammaglobin mRNA expression, CA15.3 and CEA levels in BC group as compared to benign group (p < 0.001).
  • No significant difference was observed between levels of plasma mammaglobin mRNA expression in patients with tumor's size or grade.
  • No correlation was observed with plasma mammaglobulin mRNA levels and tumor size or grading, CEA and CA15.3.
  • There was a significant difference (p < 0.05) and a positive correlation between CA 15.3 and CEA levels in patients with tumor size and grading.
  • In conclusion, plasma mammaglobin mRNA alone or in combination with CA15.3 may be used as a valuable noninvasive approach for the diagnosis and the detection of metastasis in breast cancer at the time of diagnosis.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306663.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mammaglobin A; 0 / Mucin-1; 0 / Myelin Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / RNA, Messenger; 0 / SCGB2A2 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
  •  go-up   go-down


88. Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M, Choolani M: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer; 2010;10:64
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.
  • Factors, especially those associated with cell-cycle genes, affecting the genesis and tumour progression for ovarian cancer are largely unknown.
  • Our hypothesis was supported by our tissue array experiments that showed E2F5 expression only in OEC samples but not in normal and benign tissues, and by significantly positively biased expression in serum samples done using western blotting studies.
  • E2F5 used in different combinations with CA125 for distinguishing malignant cyst from benign cyst shows that the presence of CA125 or E2F5 increases sensitivity of OEC detection to 97.9% (an increase from 87.5% if only CA125 is used) and, more importantly, the presence of both CA125 and E2F5 increases specificity of OEC to 72.5% (an increase from 55% if only CA125 is used).
  • Furthermore, detection of malignancy status in 86 cases (38 benign, 48 early and late OEC) shows that the use of E2F5 status in combination with other clinical characteristics allows for an improved detection of malignant cases with sensitivity, specificity, F-measure and accuracy of 97.92%, 97.37%, 97.92% and 97.67%, respectively.
  • CONCLUSIONS: Overall, our findings, in addition to opening a realistic possibility for improved OEC diagnosis, provide an indirect evidence that a cell-cycle regulatory protein E2F5 might play a significant role in OEC pathogenesis.
  • [MeSH-major] E2F5 Transcription Factor / physiology. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor / metabolism. CA-125 Antigen / biosynthesis. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Reproducibility of Results. Sensitivity and Specificity


89. Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C: Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J BUON; 2009 Jul-Sep;14(3):463-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
  • PURPOSE: In this study we evaluated the clinical usefulness of serum pro-I collagen peptide (PICP) and I collagen telopeptide (ICTP) as indicators of early bone metastases in patients with breast (BC), lung (LC), urinary bladder (UBC) and prostate cancer (PC).
  • ICTP and CA 15-3 were the most reliable markers for early diagnosis of bone metastases in BC.
  • Furthermore, PICP and PSA levels were significantly higher in patients with PC and bone metastases in comparison to patients with benign prostate hyperplasia (BPH) (p <0.0001) or in patients with PC without bone metastases (p <0.0005 for PICP and p <0.0001 for PSA).
  • CONCLUSION: ICTP and CA 15-3 are the most reliable markers for early diagnosis of bone metastases in BC patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Collagen Type I / metabolism
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / pathology. Carcinoembryonic Antigen / metabolism. Female. Humans. Immunoradiometric Assay. Lung Neoplasms / pathology. Male. Middle Aged. Mucin-1 / metabolism. Neoplasm Metastasis. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / pathology. Sensitivity and Specificity. Tomography, Emission-Computed. Urinary Bladder Neoplasms / pathology


90. Tsushima Y, Takahashi-Taketomi A, Endo K: Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5-T. J Magn Reson Imaging; 2009 Aug;30(2):249-55
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5-T.
  • To review the published reports concerning the apparent diffusion coefficient (ADC) value evaluation for the differentiation between malignant and benign breast tumors, articles were searched with the inclusion criteria: (a) a 1.5-T unit was used;.
  • (d) ADC values of breast tumors were reported with mean +/- standard deviation (SD).
  • Meta-analysis from 12 articles revealed that the pooled sensitivity and specificity were 0.89 (95% confidence interval [CI], 0.85-0.91) and 0.77 (95% CI, 0.69-0.84), respectively, and that only the maximum b factor correlated with the mean ADC values of malignant and benign tumors, and the noncancerous breast tissue (P< 0.05,P < 0.01,P< 0.05, respectively).
  • In conclusion, ADC evaluation is useful for the differentiation between malignant and benign breast tumors.
  • [MeSH-major] Breast Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Data Interpretation, Statistical. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19629992.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


91. Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, Timmermans-Wielenga V, Iwase T, Akiyama F, Honma N, Rank F: Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. Mol Oncol; 2009 Jun;3(3):220-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.
  • Invasive apocrine carcinomas (IACs), as defined by morphological features, correspond to 0.3-4% of all invasive ductal carcinomas (IDC), and despite the fact that they are histologically distinct from other breast lesions there are currently no standard molecular criteria available for their diagnosis and no unequivocal information as to their prognosis.
  • In an effort to address these concerns we have been using protein expression profiling technologies in combination with mass spectrometry and immunohistochemistry (IHC) to discover specific biomarkers that could allow us to molecularly characterize these lesions as well as to dissect some of the steps in the processes underlying breast apocrine metaplasia and development of precancerous apocrine lesions.
  • Establishing these apocrine-specific markers as best practice for the routine pathology evaluation of breast cancer, however, will require their validation in large cohorts of patients.
  • Towards this goal we have composed a panel of antibodies against components of an apocrine protein signature that includes probes against the apocrine-specific markers 15-prostaglandin dehydrogenase (15-PGDH), and acyl-CoA synthetase medium-chain family member 1 (ACSM1), in addition to a set of categorizing markers that are consistently expressed (AR, CD24) or not expressed (ERα, PgR, Bcl-2, and GATA-3) by apocrine metaplasia in benign breast lesions and apocrine sweat glands.
  • Samples were originally classified on the basis of cellular morphology with all cases having more than 90% of the tumour cells exhibiting cytological features typical of apocrine cells.
  • Our results demonstrate that IACs correspond to a distinct, even if heterogeneous, molecular subgroup of breast carcinomas that can be readily identified in an unbiased way using a combination of markers that recapitulate the phenotype of apocrine sweat glands (15-PGDH(+), ACSM1(+), AR(+), CD24(+), ERα(-), PgR(-), Bcl-2(-), and GATA-3(-)).
  • [MeSH-major] Apocrine Glands / metabolism. Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1313-20 [18042688.001]
  • [Cites] Acta Oncol. 2006;45(6):643-61 [16938807.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Biotechnol Annu Rev. 2008;14:143-70 [18606362.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):197-204 [17234468.001]
  • [Cites] Pathol Biol (Paris). 2009 Jun;57(4):324-33 [19070972.001]
  • [Cites] J Pathol. 2006 Mar;208(4):495-506 [16429394.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Breast. 2005 Feb;14(1):3-10 [15695074.001]
  • [Cites] Eur J Cancer. 2008 Dec;44(18):2799-805 [19008097.001]
  • [Cites] Tissue Eng Part C Methods. 2008 Sep;14(3):261-71 [18694322.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1006-12 [17105822.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):149-59 [18212769.001]
  • [Cites] Curr Opin Biotechnol. 1999 Feb;10(1):16-21 [10047502.001]
  • [Cites] Mol Oncol. 2008 Dec;2(4):368-79 [19383358.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):235-44 [17329194.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1854-63 [16002278.001]
  • [Cites] Breast J. 2008 Mar-Apr;14(2):164-8 [18248561.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R53 [18559090.001]
  • [Cites] Mol Oncol. 2008 Oct;2(3):213-22 [19383342.001]
  • [Cites] Pathol Res Pract. 2005;201(7):479-86 [16164042.001]
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):1795-809 [18632593.001]
  • [Cites] Histopathology. 2007 Mar;50(4):425-33 [17448017.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2463-71 [6254632.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2002 Dec;67(6):461-5 [12468268.001]
  • [Cites] Med Oncol. 1997 Jun;14(2):83-9 [9330267.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):339-46 [16892043.001]
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):231-6 [12610508.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):830-5 [14871808.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] Nat Methods. 2007 Apr;4(4):359-65 [17396127.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Histopathology. 2005 Aug;47(2):195-201 [16045781.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):24-32 [19383364.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] J Pathol. 2008 Oct;216(2):141-50 [18720457.001]
  • [Cites] Cancer. 1968 Apr;21(4):756-63 [4296681.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2001;2:343-72 [11701654.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):832-5 [12766589.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Histopathology. 2008 Jan;52(1):108-18 [18171422.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Nov;4(11):1391-402 [18950281.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):532-41 [3717305.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):321-49 [19383306.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Histopathology. 2008 Jan;52(1):3-10 [18171412.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):838-41 [10690175.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Pathobiology. 2008;75(2):119-31 [18544967.001]
  • [Cites] Mol Oncol. 2009 Jun;3(3):220-37 [19393583.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):201-9 [17187062.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):42-54 [19383286.001]
  • [Cites] J Gastrointest Cancer. 2007;38(2-4):78-82 [19031117.001]
  • [Cites] Breast J. 2003 Jul-Aug;9(4):335-6 [12846876.001]
  • [Cites] Pathology. 2009 Jan;41(1):68-76 [19089742.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Nature. 2005 Sep 22;437(7058):491-3 [16177777.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Feb;24(2):223-8 [3356211.001]
  • [Cites] Nat Clin Pract Urol. 2008 Jul;5(7):376-87 [18542103.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7917-25 [16140963.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):33-44 [19383365.001]
  • [Cites] Breast. 2005 Feb;14(1):1-2 [15695073.001]
  • [Cites] Breast Cancer Res. 2007;9(3):R30 [17504517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Int J Clin Pract. 2008 Mar;62(3):444-9 [18194278.001]
  • [Cites] Mol Oncol. 2007 Sep;1(2):144-59 [18443658.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1041-55 [17129787.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):580-92 [17668425.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • (PMID = 19393583.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


92. Branchini G, Schneider L, Cericatto R, Capp E, Brum IS: Progesterone receptors A and B and estrogen receptor alpha expression in normal breast tissue and fibroadenomas. Endocrine; 2009 Jun;35(3):459-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptors A and B and estrogen receptor alpha expression in normal breast tissue and fibroadenomas.
  • Fibroadenomas are the most common benign breast tumors, occurring mainly in young women.
  • Their responses to the hormonal environment are similar to those of normal breast tissue, which suggests that steroid receptors may play a role in tumor development.
  • We evaluated the gene and protein expression of progesterone receptors A and B (PRA and PRB) and the protein expression of estrogen receptor alpha (ER-alpha) in fibroadenoma samples, comparing with adjacent normal breast tissue, from 11 premenopausal women.
  • No alterations in the PRs gene and protein expression and the ER-alpha protein expression were observed between the follicular and luteal phases, in normal breast versus fibroadenomas.
  • Protein levels of PRA and PRB were higher in fibroadenomas compared to normal breast tissue (P = 0.038 and P = 0.031), while the PRs mRNA levels were similar in both tissues (P = 0.721 and P = 0.139).
  • There were no differences in ER-alpha protein expression between normal breast tissue and fibroadenomas (P = 0.508).
  • Our data suggest a role of PRs in the growth and development of fibroadenomas, although without alterations of the PRA:PRB ratio in these tumors.
  • The absence of alterations in ER-alpha protein levels could be a characteristic behavior of fibroadenomas, unlike breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Estrogen Receptor alpha / genetics. Fibroadenoma / genetics. Mammary Glands, Human / metabolism. Receptors, Progesterone / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19367380.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone; 0 / progesterone receptor A; 0 / progesterone receptor B
  •  go-up   go-down


93. Nakaguro M, Suzuki Y, Ichihara S, Kobayashi TK, Ono K: Epithelial inclusion cyst arising in an intramammary lymph node: case report with cytologic findings. Diagn Cytopathol; 2009 Mar;37(3):199-202
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of squamous cells can lead to the erroneous diagnosis of more common breast lesions, such as squamous cell carcinoma or metaplastic carcinoma.
  • Contrary to these more sinister diagnoses, EIC arising in an intramammary lymph node is a benign condition.
  • As this rare lesion sometimes mimics a neoplasm both clinically and radiographically, awareness of this entity is important to prevent over treatment.
  • [MeSH-major] Breast Cyst / pathology. Breast Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19177497.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Zheng HY, Chen Q, Ye YB, Huang WW: [mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR]. Zhonghua Yi Xue Za Zhi; 2008 Aug 19;88(32):2267-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR].
  • OBJECTIVE: To explore the clinical significance of detection of cytokeratin 19 (CK19) mRNA and carcinoembryonic antigen (CEA) mRNA expression in the diagnosis of micrometastasis in the peripheral blood of patients with breast cancer, and the relationship with other clinicopathological characteristics.
  • METHODS: Peripheral blood samples were collected from 28 normal female healthy volunteers, 20 patients with benign breast disease, and 108 patients with breast cancer (88 had undergone operation and 20 with metastasis).
  • None of the 20 patients with benign breast disease was positive for CEA mRNA, but one was positive for CK19 mRNA (5%).
  • Of the 108 patients with breast cancer, 26 (24.1%) were positive for CK19 mRNA, 23 (21.3%) were positive for CEA mRNA, and 15 (13.9%) were positive for both CK19 mRNA and CEA mRNA.
  • The positive rates of CK19 mRNA and/or CEA mRNA of the metastatic breast cancer patients were higher than those of the operable breast cancer patients.
  • Statistically significant differences in tumor size, clinical stage, and expression levels of k(i)67, variant exon 6 containing isoforms of CD44 (CD44v6), and vascular endothelial growth factor (VEGF) were found between the operable breast cancer patients with micrometastasis in peripheral blood and the patients without micrometastasis (all P < 0.05).
  • And there was no statistically significant difference between the two groups in age, tumor location, pathological histological type, nodal metastasis, and expression levels of estrogen receptor (ER), pregnant receptor (PR), CerbB2, and matrix metalloproteinase-9 (MMP9) (all P > 0.05).
  • Multivariate analysis showed that tumor size, clinical stage, expressions of ki67, CD44v6, and VEGF were associated with micrometastasis in peripheral blood.
  • CONCLUSION: The combined detection of CK19 and CEA mRNA raises the detection rate of micrometastasis in the peripheral blood of breast cancer patients.
  • Tumor size, clinical stage, expressions of ki67, CD44v6, and VEGF are effective predictors of micrometastasis in the peripheral blood of breast cancer patients.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoembryonic Antigen / blood. Gene Expression Regulation, Neoplastic. Keratin-19 / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Logistic Models. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087676.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


95. Riebe E, Günther K, Schulz K, Köhler G, Schimming A, Schwesinger G, Ohlinger R: Recurrent disease after breast preserving therapy (BPT) and radiation therapy for breast cancer--diagnostic yield of palpation, mammography and ultrasonography. Ultraschall Med; 2007 Aug;28(4):394-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent disease after breast preserving therapy (BPT) and radiation therapy for breast cancer--diagnostic yield of palpation, mammography and ultrasonography.
  • PURPOSE: According to the S-3 guidelines for the diagnosis and treatment of breast cancer, only palpation and mammography are mandatory follow-up examinations.
  • Aiming to elucidate the diagnostic yield for detecting recurrent disease after breast-preserving therapy (BPT) and radiation treatment, we analysed the sensitivity of palpation, mammography, ultrasonography, and combinations of these methods.
  • MATERIALS AND METHODS: Over a period of 12 years, 27 suspicious lesions in patients status post BPT and radiation therapy were biopsied (histologic results: 16 benign lesions: 59.3 %, 11 malignant lesions: 40.7 %).
  • Prior to biopsy, the benign or malignant character of each lesion was predicted by palpation, mammography and ultrasonography (BIRADS).
  • [MeSH-major] Breast Neoplasms / surgery. Breast Neoplasms / ultrasonography. Neoplasm Recurrence, Local / ultrasonography

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17610177.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Shaker OG, Ay El-Deen MA, Abd El-Rahim MT, Talaat RM: Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients. Tumori; 2006 Nov-Dec;92(6):524-30
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients.
  • AIMS AND BACKGROUND: This study aims to detect the expression of E-selectin in tissue and the serum level of its soluble form in patients with primary breast cancer and benign breast tumors and to correlate the results with the clinicopathological data of the subjects.
  • Group A comprised 30 patients with primary breast cancer, group B 9 patients with benign breast tumors, and group C 11 healthy control women undergoing reduction mammoplasty.
  • E-selectin gene expression was investigated in breast tissues by PCR techniques and soluble E-selectin was measured in sera by ELISA.
  • It was expressed in 61.5% of patients with grade 2 breast cancer and in 82.4% of patients with grade 3 breast cancer.
  • E-selectin gene expression was detected in 60%, 73.3% and 100% of patients with stage II, III and IV tumors, respectively.
  • It was detected in 81.8% of patients with node-positive primary breast cancer and in 50% of patients with node-negative cancer.
  • E-selectin was found on the membranes of peritumoral endothelial cells while it was not found on breast epithelial cells.
  • They increased significantly with increasing breast cancer stage (P < 0.001) and were significantly higher in patients with lymph node involvement than in patients without node involvement (P < 0.001).
  • CONCLUSIONS: The studied marker showed associations with established prognostic parameters such as lymph node involvement and histological tumor grade.
  • E-selectin can be regarded as a promising strategy in improving tumor therapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. E-Selectin / metabolism. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Diseases / metabolism. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. In Situ Hybridization. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260494.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E-Selectin
  •  go-up   go-down


97. Gogo-Abite M, Seleye-Fubara D, Jamabo RS: Fibroadenoma coexisting with infiltrating ductal carcinoma--a case report. Niger J Med; 2005 Apr-Jun;14(2):221-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fibroadenomas are benign breast tumours that are commonly diagnosed in young women in their 20's and early 30's.
  • Occurrence of malignancy in the breasts of these women is very rare.
  • METHOD AND RESULT: We report a case of an infiltrating ductal carcinoma within an otherwise benign fibroadenoma in a 23-year-old woman.
  • She presented with a lump, approximately 7cm in diameter, in her right breast.
  • CONCLUSION: Fibroadenomas are commonly diagnosed in patients in their 20's when the risk of developing breast cancer is extremely rare.
  • Despite this rarity all excised breast lumps should be subjected to histopathological evaluation in order to avoid a diagnostic pitfall.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083250.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


98. Baez E, Strathmann K, Vetter M, Madjar H, Hackelöer BJ: Likelihood of malignancy in breast lesions characterised by ultrasound with a combined diagnostic score. Ultrasound Med Biol; 2005 Feb;31(2):179-84
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Likelihood of malignancy in breast lesions characterised by ultrasound with a combined diagnostic score.
  • To determine the positive predictive value of breast ultrasound (US) categories and US features, isolated and in combination, 398 consecutive sonographically diagnosed breast tumours with histologic or cytologic diagnosis were reviewed.
  • Tumour characterisation and the sonographer's diagnoses were recorded prospectively using the diagnostic classification of the European Society of Mastology (EUSOMA) (U2 = probably benign lesion, U3 = an abnormality present of indeterminate significance, U4 = features suspicious of malignancy).
  • US-guided biopsy revealed 338 benign and 60 (55 invasive and 5 noninvasive) malignant lesions.
  • If all breast tumours classified U3 and U4 were to be tested, every second biopsy (48.3%) would have revealed a carcinoma with a negative predictive value of 99.3%.
  • The frequency of carcinoma in sonographically benign lesions (U2 or score 1) was 0.7 and 2.2%, respectively, an incidence similar to that with mammographic lesions classified as BI-RADS 3 (Breast Imaging Reporting and Data System, probably benign, short interval follow-up suggested).
  • Thus, given that clinical symptoms and real-time imaging influence the sonographer's interpretation, the proposed diagnostic score can improve the diagnostic accuracy of the breast sonogram with the result of reducing invasive testing and maintaining a high detection rate.
  • [MeSH-major] Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle / methods. Carcinoma in Situ / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Lobular / ultrasonography. Female. Humans. Middle Aged. Neoplasm Invasiveness / ultrasonography. Prospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708456.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Thitaikumar A, Mobbs LM, Kraemer-Chant CM, Garra BS, Ophir J: Breast tumor classification using axial shear strain elastography: a feasibility study. Phys Med Biol; 2008 Sep 7;53(17):4809-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast tumor classification using axial shear strain elastography: a feasibility study.
  • In this paper, we report a feasibility study on the utility of the axial-shear strain elastograms in the classification of in vivo breast tumor as being benign or malignant.
  • The study was performed using data sets obtained from 15 benign and 15 malignant cases that were biopsy proven.
  • The observers also outlined the tumor area on the corresponding sonogram, which was used to normalize the area of the axial-shear strain region.
  • First, the result indicates that the observers consistently ( approximately 82% of the cases) noticed the characteristic pattern of the axial-shear strain distribution data as predicted in the previous simulation studies, i.e. alternating regions of positive and negative axial-shear strain values around the tumor-background interface.
  • Second, the analysis of the result suggests that in approximately 57% of the cases in which the observers did not visualize tumor in the sonogram, the elastograms helped them to locate the tumor.
  • Feature values between 0.46 and 0.75 may result in an overlap between benign and malignant cases.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Elasticity Imaging Techniques / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701768.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Suga K, Kawakami Y, Hiyama A, Matsunaga N: Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan. Ann Nucl Med; 2009 Jun;23(4):399-407
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
  • OBJECTIVE: To evaluate the ability of dual-time point F-18-fluorodeoxy-glucose (FDG) PET/CT scans to differentiate FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer.
  • METHODS: A total of 64 FDG-avid recurrent lesions (local tumor recurrence or lymph node metastases) in 52 patients and 38 FDG-avid compromised benign lesions after surgery in 37 patients were included in the study.
  • RESULTS: The average early SUVmax, delayed SUVmax and DeltaSUVmax% were 4.9 +/- 2.6, 6.0 +/- 3.6 and 18.2% +/- 18.8 in FDG-avid recurrent lesions, and 2.1 +/- 0.8, 1.8 +/- 1.0 and -17.8% +/- 21.3 in FDG-avid benign lesions, respectively.
  • Delayed SUVmax was significantly increased compared with early SUVmax in recurrent lesions (P < 0.0001), while it was decreased in benign lesions (P < 0.0001).
  • All the three parameters in recurrent lesions were significantly higher than those in benign lesions (P < 0.0001).
  • CONCLUSIONS: This approach with SUVmax estimation appears to improve the differentiation between FDG-avid loco-regional recurrent of breast cancer and compromised benign lesions after surgery, since delayed scanning significantly enhances the difference in FDG uptake between these lesions.
  • [MeSH-major] Breast Neoplasms / surgery. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Positron-Emission Tomography. ROC Curve. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452249.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down






Advertisement